A Phase 3 interventional study of CP-690,550 and CP-690,550 in Psoriasis, sponsored by Pfizer. Completed at 87 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-26.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing tofacitinib in Psoriasis — 4 open to participants now, 4 under way, 1 of them phase 3. tofacitinib · Psoriasis.
Among the 19 studies testing tofacitinib in Psoriasis, this one is the 6th largest by enrollment, is one of 3 that started in 2010, is one of 9 in phase 3, and was the 4th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →4 of the 19 studies testing tofacitinib in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Lahore General Hospital · Sites in Pakistan
Ages 18–70 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18+
Pak Emirates Military Hospital
Ages 18–70
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 666 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 135 across the 19 interventional studies. Of the 15 that completed or were terminated, 15 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 6 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
57 studies in Psoriasis by Pfizer: none open now, none under way, none of them phase 3. Of 56 finished, 46 (82%) have results posted.
Among the 57 studies in Psoriasis by Pfizer, this one is the 8th largest by enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2010, is one of 10 in phase 3, and was the 30th registered.
Pfizer’s Psoriasis studies by the year they started, since 2002.
1 of the studies testing tofacitinib in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07581418Pak Emirates Military HospitalComparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing tofacitinib in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 57 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at various timepoints during the 16 week double blind active or placebo treatment period; 2) evaluate the regain of efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) following 4 -16 weeks of CP 690,550 treatment withdrawal and subsequent re treatment; and 3) evaluate the safety and tolerability of CP 690,550 (5 mg BID and 10 mg BID) in subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
Drug: CP-690,550
Continuous active treatment (CP-690,550) for 56 weeks
Drug: CP-690,550
Continuous active treatment (CP-690,550) for 24 weeks, followed by treatment withdrawal (placebo treatment) for 4-16 weeks, followed by active treatment (CP-690,550) for 16-28 weeks
Drug: CP-690,550
Continuous active treatment (CP-690,550) for 56 weeks
Drug: CP-690,550
10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
10 mg oral BID
5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
5 mg oral BID
Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B)
The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response defined as at least a 75 percent (%) reduction in PASI relative to baseline.
Time frame: Weeks 4, 8 12, and 16 (Period B)
Percentage of Participants Maintaining a Physician's Global Assessment (PGA) Response During the Double-Blind Treatment Withdrawal (Period B)
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response defined as 0 (clear) or 1 (almost clear).
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Percentage of Participants Achieving a PASI75 Response During CP-690,550 Re-Treatment (Period C) Among Those Who Had a Greater Than (>)50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)
The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. PASI75 response is defined as at least 75% reduction in PASI relative to Baseline/Day 1. Baseline defined as the last observation up to first dosing date in Period C. PASI responses at each period were relative to Baseline-A, where Baseline-A was defined as the last observation up to first dosing date in Period A.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Percentage of Participants Achieving a PGA Response of Clear or Almost Clear During CP-690,550 Re-treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe During Double-Blind Treatment Withdrawal (Period B)
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Median Time to PASI75 Response During Initial CP-690,550 Treatment (Period A)
The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. PASI75 response defined as 75% reduction in PASI relative to baseline.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Median Time to PGA Response of Clear or Almost Clear During Initial CP-690,550 Treatment (Period A)
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response defined as 0 (clear) or 1 (almost clear).
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participants Achieving Both a PASI50-75 Response and Dermatology Life Quality Index (DLQI) ≤5 Response During Initial CP-690,550 Treatment (Period A)
PASI50-75 response defined as a reduction of at least 50% but less than 75%. The DLQI is a general dermatology questionnaire that consists of 10 items that assess participant health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participant Maintaining an Adequate Response During the Double-Blind Treatment Withdrawal (Period B)
Adequate response defined as \>50% reduction of the Visit A4/Week 24 (last visit in Period A) PASI response.
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Median Time to Loss of Adequate Response During the Double-Blind Treatment Withdrawal (Period B)
Adequate response defined as \>50% reduction of the Visit A4/Week 24 (last visit in Period A) PASI response.
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Period Between Week 24 and Week 32 (Period B)
The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI responses at each period are relative to Baseline-A where Baseline-A was defined as the last observation up to first dosing date in Period A. Weeks 4 and 8 are relative to the Period B baseline and are the same as Weeks 28 and 32, which are relative to Period A baseline. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.
Time frame: Weeks 4 and 8 (Period B)
Percentage of Participants With PASI Score ≥125% of Baseline-A or New Type of Psoriasis (Pustular, Erythrodermic) During the Double-Blind Treatment Withdrawal (Period B)
The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI responses at each period are relative to Baseline-A where Baseline-A was defined as the last observation up to first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Percentage of Participants Maintaining Adequate PASI Response and Maintaining PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)
Adequate PASI response defined as less than or equal to 50% reduction of the Visit A4/Week 24 PASI Response.
Time frame: Week 24 (Period A) and Weeks 4, 8, 12, and 16 (Period B)
Median Time to Loss of >50% of the Visit A4/Week 24 PASI Response and Loss of PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B)
Time frame: Week 24 (Period A) and Weeks 4, 8, 12, and 16 (Period B)
Percentage of Participants Regaining PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C
PASI75 response defined as at least a 75% reduction in PASI relative to baseline.
Time frame: Weeks 4, 8, and 16 (Period C)
Median Time to Regain PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C
PASI75 response defined as at least a 75% reduction in PASI relative to baseline.
Time frame: Weeks 4, 8, and 16 (Period C)
Percentage of Participants Regaining PASI75 and PGA Response (PGA of Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Who Had Lost Both PASI75 Response and PGA Response at the Beginning of Period C
PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses at each period are relative to Baseline-A, where Baseline-A is defined as the last observation up to first dosing date in Period A. 95% confidence interval constructed using the normal approximation to the binomial distribution of one-sample proportion.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Median Time to PASI75 Response During CP-690,550 Re-Treatment (Period C) For Those Who Had a >50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B)
PASI75 response defined as at least a 75% reduction in PASI relative to baseline.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Median Time to PGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe at the Beginning of Period C
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Percentage of Participants With a PASI75 Response During the Initial CP-690,550 Treatment (Period A)
PASI75 response defined as at least a 75% reduction in PASI relative to baseline. Baseline defined as the last observation up to the first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participants With a PASI75 Response During Double-Blind Withdrawal Treatment (Period B)
PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses in each period are relative to Baseline-A, where Baseline-A is defined as the last observation until first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Percentage of Participants With a PASI75 Response During the CP-690,550 Re-Treatment (Period C)
PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses in each period are relative to Baseline-A, where Baseline-A is defined as the last observation until first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.
Time frame: Weeks 4, 8, and 16 (Period C)
Percentage of Participants With PGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)
PGA response was defined as 0 (clear) or 1 (almost clear) on a 5-point scale where 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participants With PGA Response of Clear or Almost Clear During Double-Blind Withdrawal Treatment (Period B)
PGA response was defined as 0 (clear) or 1 (almost clear) on a 5-point scale where 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Percentage of Participants With PGA Response of Clear or Almost Clear During the CP-690,550 Re-Treatment (Period C)
PGA response was defined as 0 (clear) or 1 (almost clear) on a 5-point scale where 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.
Time frame: Weeks 4, 8, and 16 (Period C)
Mean Total Percent of Psoriatic Body Surface Area (BSA) During Initial CP-690,550 Treatment (Period A)
Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)
Mean Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)
Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)
Mean Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)
Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Mean Change From Baseline in Total Percent of Psoriatic BSA During Initial CP-690,550 Treatment (Period A)
Baseline defined as the last observation up to first dosing date in Period A.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Mean Change From Baseline in Total Percent of Psoriatic BSA During Double-Blind Treatment Withdrawal (Period B)
Baseline defined as the last observation up to first dosing date in Period B.
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Mean Change From Baseline in Total Percent of Psoriatic BSA During CP-690,550 Re-Treatment (Period C)
Baseline was defined as the last observation until first dosing date in Period C.
Time frame: Weeks 4, 8, and 16 (Period C)
Mean Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)
Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)
Mean Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)
Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)
Mean Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)
Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Initial CP-690,550 Treatment (Period A)
Baseline defined as the last observation up to first dosing date in Period A.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During Double-Blind Treatment Withdrawal (Period B)
Baseline defined as the last observation up to first dosing date in Period B.
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Mean Change From Baseline in Percent of Psoriatic BSA by Body Region During CP-690,550 Re-Treatment (Period C)
Baseline defined as the last observation up to first dosing date in Period C.
Time frame: Weeks 4, 8, and 16 (Period C)
Mean PASI Score During Initial CP-690,550 Treatment (Period A)
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.
Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)
Mean PASI Score During Double-Blind Treatment Withdrawal (Period B)
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.
Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)
Mean PASI Score During the CP-690,550 Re-Treatment (Period C)
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Mean Change From Baseline-A in PASI Score During Initial CP-690,550 Treatment (Period A)
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Mean Change From Baseline-B in PASI Score During Double-Blind Treatment Withdrawal (Period B)
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-B defined as last observation up to first dosing date in Period B.
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Mean Change From Baseline-C in PASI Score During the CP-690,550 Re-Treatment (Period C)
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-C defined as last observation up to first dosing date in Period C.
Time frame: Weeks 4, 8, and 16 (Period C)
Mean PASI Component Scores During Initial CP-690,550 Treatment (Period A)
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.
Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)
Mean PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.
Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)
Mean PASI Component Scores During the CP-690,550 Re-Treatment (Period C)
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Mean Change From Baseline in PASI Component Scores During Initial CP-690,550 Treatment (Period A)
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Mean Change From Baseline in PASI Component Scores During Double-Blind Treatment Withdrawal (Period B)
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Mean Change From Baseline in PASI Component Scores During the CP-690,550 Re-Treatment (Period C)
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.
Time frame: Weeks 4, 8, and 16 (Period C)
Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During Period A
PASI quantifies the severity of psoriasis based on both lesion severity and the percent of BSA) affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of the body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During Period A
PASI quantifies the severity of psoriasis based on both lesion severity and the percent of BSA) affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of the body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participants Achieving at Least a 100% Reduction in PASI Relative to Baseline-A (PASI100) During Period A
PASI quantifies the severity of psoriasis based on both lesion severity and the percent of BSA) affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of the body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participants Achieving at Least a 50% Reduction in PASI Relative to Baseline-A (PASI50) During the CP-690,550 Re-Treatment (Period C)
PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Percentage of Participants Achieving at Least a 90% Reduction in PASI Relative to Baseline-A (PASI90) During the CP-690,550 Re-Treatment (Period C)
PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Percentage of Participants Achieving 100% Reduction in PASI Relative to Baseline-A (PASI100) During the CP-690,550 Re-Treatment (Period C)
PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Initial CP-690,550 Treatment (Period A)
PASI quantifies the severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During Double-Blind Treatment Withdrawal (Period B)
PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Percentage of Participants With a PASI Score ≥125% of the Baseline-A PASI Score During the CP-690,550 Re-Treatment (Period C)
PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
Time frame: Weeks 4, 8, and 16 (Period C)
Mean Itch Severity Item (ISI) Score During the Initial CP-690,550 Treatment (Period A)
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)
Mean ISI Score During the Double-Blind Treatment Withdrawal (Period B)
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)
Mean ISI Score During the CP-690,550 Re-Treatment (Period C)
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Mean Change From Baseline-A in ISI Score During the Initial CP-690,550 Treatment (Period A)
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. Baseline-A defined as the last observation up to first dosing date in Period A.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Mean Change From Baseline-B in ISI Score During the Double-Blind Treatment Withdrawal (Period B)
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. Baseline-B defined as the last observation up to first dosing date in Period B.
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Mean Change From Baseline-C in ISI Score During the CP-690,550 Re-Treatment (Period C)
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. Baseline-C defined as the last observation up to first dosing date in Period C.
Time frame: Weeks 4, 8, and 16 (Period C)
Percentage of Participants With ISI Score of 0 During the Initial CP-690,550 Treatment (Period A)
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participants With ISI Score of 0 During CP-690,550 Re-Treatment (Period C)
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Percentage of Participants Achieving ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participants Achieving an ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C)
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Percentage of Participants Achieving ISI ≥2-Point Reduction During the Initial CP-690,550 Treatment (Period A)
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participants Achieving ISI ≥2-Point Reduction During the CP-690,550 Re-Treatment (Period C)
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Weeks 4, 8, and 16 (Period C)
ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Median Time to ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A)
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
ISI Score of ≤1 During CP-690,550 Re-Treatment (Period C) - Percentage of Participants With a Response
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Weeks 4, 8, and 16 (Period C)
Median Time to ISI Score of ≤1 During the CP-690,550 Re-Treatment (Period C)
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Weeks 4, 8, and 16 (Period C)
ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A) - Percentage of Participants With a Response
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Median Time to ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A)
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) - Percentage of Participant With a Response
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Weeks 4, 8, and 16 (Period C)
Median Time to ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C)
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
Time frame: Weeks 4, 8, and 16 (Period C)
Mean Dermatology Life Quality Index (DLQI) Score During the Initial CP-690,550 Treatment (Period A)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)
Mean DLQI Score During the CP-690,550 Re-Treatment (Period C)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Mean DLQI Score During the Double-Blind Treatment Withdrawal (Period B)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)
Mean Change From Baseline-A in DLQI Score During the Initial CP-690,550 Treatment (Period A)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-A defined as the last observation up to first dosing date in Period A.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Mean Change From Baseline-B in DLQI Score During the Double-Blind Treatment Withdrawal (Period B)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-B defined as the last observation up to first dosing date in Period B.
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Mean Change From Baseline-C in DLQI Score During the CP-690,550 Re-Treatment (Period C)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-C defined as the last observation up to first dosing date in Period C.
Time frame: Weeks 4, 8, and 16 (Period C)
Mean DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).
Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)
Mean DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).
Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)
Mean DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Mean Change From Baseline-A in DLQI Subscale Scores During the Initial CP-690,550 Treatment (Period A)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-A defined as the last observation up to first dosing date in Period A.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Mean Change From Baseline-B in DLQI Subscale Scores During the Double-Blind Treatment Withdrawal (Period B)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-B defined as the last observation up to first dosing date in Period B.
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Mean Change From Baseline-C in DLQI Subscale Scores During the CP-690,550 Re-Treatment (Period C)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-C defined as the last observation up to first dosing date in Period C.
Time frame: Weeks 4, 8, and 16 (Period C)
Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-B Response During Double-Blind Treatment Withdrawal (Period B)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Percentage of Participants Achieving DLQI ≥5 Point Reduction From Baseline-C Response During CP-690,550 Re-Treatment (Period C)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-C defined as the last observation up to first dosing date in Period C.
Time frame: Weeks 4, 8, and 16 (Period C)
Percentage of Participants Achieving DLQI ≤1 Response During the Initial CP-690,550 Treatment (Period A)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participants Achieving DLQI ≤1 Response During Double-Blind Treatment Withdrawal (Period B)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Percentage of Participants Achieving DLQI ≤1 Response During CP-690,550 Re-Treatment (Period C)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Percentage of Participants by DLQI Severity Category During the Initial CP-690,550 Treatment (Period A)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Severity is measured using the following categories of scores: 0-1=no effect on patients' lives; 2-5=small effect; 6-10=moderate effect; 11-20=very large effect; 21-30=extremely large effect.
Time frame: Baseline and Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participants With DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Time frame: Weeks 4, 8, and 16 (Period C)
Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C)
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
Time frame: Weeks 4, 8, and 16 (Period C)
Mean Short-Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores During the Initial CP-690,550 Treatment (Period A)
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and standard deviations (SDs) of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.
Time frame: Baseline and Week 24 (Period A)
Mean SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and SDs of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.
Time frame: Baseline and Week 56 (Period C)
Mean Change From Baseline-A in SF-36 PCS and MCS Scores During the Initial CP-690,550 Treatment (Period A)
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and SDs of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.
Time frame: Week 24 (Period A)
Mean Change From Baseline-C in SF-36 PCS and MCS Scores During CP-690,550 Re-Treatment (Period C)
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and SDs of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.
Time frame: Week 56 (Period C)
Mean SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.
Time frame: Baseline and Week 24 (Period A)
Mean SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.
Time frame: Baseline and Week 56 (Period C)
Mean Change From Baseline-A in SF-36 Domain Scores During the Initial CP-690,550 Treatment (Period A)
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life. Baseline-A defined as the last observation up to first dosing date in Period A.
Time frame: Week 24 (Period A)
Mean Change From Baseline-C in SF-36 Domain Scores During CP-690,550 Re-Treatment (Period C)
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life. Baseline-C defined as the last observation up to first dosing date in Period C.
Time frame: Week 56 (Period C)
Percentage of Participants in Each Patient Global Assessment (PtGA) of Psoriasis Category During the Initial CP-690,550 Treatment (Period A)
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe
Time frame: Baseline and Weeks 4, 8, 16 and 24 (Period A)
Percentage of Participants in Each PtGA of Psoriasis Category During Double-Blind Treatment Withdrawal (Period B)
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe.
Time frame: Baseline and Weeks 4, 8, 12, and 16 (Period B)
Percentage of Participants in Each PtGA of Psoriasis Category During CP-690,550 Re-Treatment (Period C)
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Percentage of Participants With PtGA Response of Clear or Almost Clear During the Initial CP-690,550 Treatment (Period A)
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. Response defined as score of 0 or 1.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participants With PtGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PtGA of Mild, Moderate or Severe During CP-690,550 Treatment Withdrawal (Period B)
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. Response defined as score of 0 or 1.
Time frame: Baseline and Weeks 4, 8, and 16 (Period C)
Percentage of Participants Maintaining PtGA Response of Clear or Almost Clear During the Double-Blind Treatment Withdrawal (Period B) Among Participants Who Had a Response of Clear or Almost Clear at Beginning of Period B
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. Response defined as score of 0 or 1.
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Mean EuroQol 5 Dimensions (EQ-5D) Health State Profile Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Mean EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
Time frame: Baseline and Week 56 (Period C)
Mean Change From Baseline-A in EQ-5D Utility Score and VAS Scores During the Initial CP-690,550 Treatment Period (Period A)
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. Baseline-A defined as the last observation up to first dosing date in Period A.
Time frame: Week 24 (Period A)
Mean Change From Baseline-C in EQ-5D Utility Score and VAS Scores During CP-690,550 Re-Treatment (Period C)
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. Baseline-C defined as the last observation up to first dosing date in Period C.
Time frame: Week 56 (Period C)
Mean EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed").
Time frame: Baseline and Week 24 (Period A)
Mean EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed").
Time frame: Baseline and Week 56 (Period C)
Mean Change From Baseline-A in EQ-5D Domain Scores During the Initial CP-690,550 Treatment Period (Period A)
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Baseline-A defined as the last observation up to first dosing date in Period A.
Time frame: Week 24 (Period A)
Mean Change From Baseline-C in EQ-5D Domain Scores During CP-690,550 Re-Treatment (Period C)
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Baseline-C defined as the last observation up to first dosing date in Period C.
Time frame: Week 56 (Period C)
Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During the Initial CP-690,550 Treatment (Period A)
Time frame: Weeks 4, 8, 16, and 24 (Period A)
Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During Double-Blind Treatment Withdrawal (Period B)
Time frame: Weeks 4, 8, 12, and 16 (Period B)
Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During CP-690,550 Re-Treatment (Period C)
Time frame: Weeks 4, 8, and 16 (Period C)
| Milestone | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) | CP-690,550 5 mg/CP-690,550 5 mg/CP-690,550 5 mg | CP-690,550 5 mg/Placebo/CP-690,550 5 mg | CP-690,550 10 mg/CP-690,550 10 mg/CP-690,550 10 mg | CP-690,550 10 mg / Placebo / CP-690,550 10 mg |
|---|---|---|---|---|---|---|
| Started | 218 | 157 | 31 | 82 | 45 | 133 |
| Completed | 10 | 5 | 25 | 70 | 39 | 107 |
| Not completed | 208 | 152 | 6 | 12 | 6 | 26 |
| Withdrew: Lack of efficacy | 156 | 99 | 0 | 2 | 2 | 5 |
| Withdrew: Protocol violation | 1 | 2 | 0 | 1 | 1 | 2 |
| Withdrew: Lost to follow-up | 15 | 16 | 2 | 1 | 1 | 4 |
| Withdrew: Screen failure | 1 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 14 | 10 | 2 | 5 | 0 | 6 |
| Withdrew: Study terminated by sponsor | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 9 | 10 | 1 | 2 | 1 | 5 |
| Withdrew: Adverse event | 10 | 14 | 1 | 0 | 1 | 4 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 |
The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of body surface area (BSA) affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response defined as at least a 75 percent (%) reduction in PASI relative to baseline.
| percentage of participants | CP-690,550 5 mg (Period B) | Placebo for CP-690,550 5 mg (Period B) | CP-690,550 10 mg (Period B) | Placebo for 10 mg CP-690,550 |
|---|---|---|---|---|
| Week 4 | 90.3 (72.9 to 96.8) | 63.4 (52.0 to 72.8) | 91.1 (78.0 to 96.6) | 61.4 (52.5 to 69.1) |
| Week 8 | 70.3 (50.6 to 83.3) | 36.2 (25.8 to 46.7) | 86.6 (72.5 to 93.7) | 39.6 (31.2 to 47.9) |
| Week 12 | 63.2 (43.4 to 77.7) | 32.4 (22.4 to 42.7) | 77.2 (61.7 to 87.0) | 33.4 (25.4 to 41.5) |
| Week 16 | 56.2 (36.7 to 71.8) | 23.3 (14.7 to 33.1) | 62.3 (45.8 to 75.0) | 26.1 (18.8 to 33.9) |
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response defined as 0 (clear) or 1 (almost clear).
| percentage of participants | CP-690,550 5 mg BID (Period B) | Placebo for CP-690,550 5 mg (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 |
|---|---|---|---|---|
| Week 4 | 80.6 (61.9 to 90.8) | 57.3 (45.9 to 67.2) | 80.0 (65.1 to 89.1) | 52.3 (43.4 to 60.4) |
| Week 8 | 67.7 (48.4 to 81.2) | 34.4 (24.2 to 44.8) | 80.0 (65.1 to 89.1) | 32.5 (24.6 to 40.6) |
| Week 12 | 60.6 (41.1 to 75.4) | 26.7 (17.6 to 36.8) | 66.3 (50.4 to 78.1) | 23.8 (16.8 to 31.4) |
| Week 16 | 49.9 (31.0 to 66.2) | 22.9 (14.4 to 32.6) | 63.9 (48.0 to 76.1) | 18.0 (11.9 to 25.2) |
The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. PASI75 response is defined as at least 75% reduction in PASI relative to Baseline/Day 1. Baseline defined as the last observation up to first dosing date in Period C. PASI responses at each period were relative to Baseline-A, where Baseline-A was defined as the last observation up to first dosing date in Period A.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline | 50.00 (0.00 to 100.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Week 4 | 100.00 (100.00 to 100.00) | 13.16 (2.41 to 23.91) | 0.00 (0.00 to 0.00) | 40.68 (28.14 to 53.21) |
| Week 8 | 100.00 (100.00 to 100.00) | 31.58 (16.80 to 46.36) | 0.00 (0.00 to 0.00) | 49.15 (36.40 to 61.91) |
| Week 16 | 50.00 (0.00 to 100.00) | 31.58 (16.80 to 46.36) | 0.00 (0.00 to 0.00) | 50.85 (38.09 to 63.60) |
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe).
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline | 23.08 (0.17 to 45.98) | 5.17 (0.0 to 10.87) | 6.67 (0.0 to 19.29) | 7.14 (2.04 to 12.24) |
| Week 4 | 23.08 (0.17 to 45.98) | 25.86 (14.59 to 37.13) | 33.33 (9.48 to 57.19) | 51.02 (41.12 to 60.92) |
| Week 8 | 30.77 (5.68 to 55.86) | 39.66 (27.07 to 52.24) | 40.0 (15.21 to 64.79) | 55.10 (45.25 to 64.95) |
| Week 16 | 30.77 (5.68 to 55.86) | 41.38 (28.70 to 54.05) | 53.33 (28.09 to 78.58) | 48.98 (39.08 to 58.88) |
The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. PASI75 response defined as 75% reduction in PASI relative to baseline.
| weeks | CP-690,550 5 mg (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Median Time to PASI75 Response During Initial CP-690,550 Treatment (Period A) | 24.3 (24.1 to 24.6) | 8.7 (8.1 to 15.4) |
The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response defined as 0 (clear) or 1 (almost clear).
| weeks | CP-690,550 5 mg (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Median Time to PGA Response of Clear or Almost Clear During Initial CP-690,550 Treatment (Period A) | 24.1 (16.6 to 24.4) | 8.1 (NA to NA) |
PASI50-75 response defined as a reduction of at least 50% but less than 75%. The DLQI is a general dermatology questionnaire that consists of 10 items that assess participant health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
| percentage of participants | CP-690,550 5 mg (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 | 12.69 (9.10 to 16.27) | 21.19 (16.82 to 25.57) |
| Week 8 | 18.73 (14.53 to 22.93) | 19.40 (15.17 to 23.64) |
| Week 16 | 18.13 (13.98 to 22.28) | 13.13 (9.52 to 16.75) |
| Week 24 | 10.88 (7.52 to 14.23) | 10.15 (6.92 to 13.38) |
Adequate response defined as \>50% reduction of the Visit A4/Week 24 (last visit in Period A) PASI response.
| percentage of participants | CP-690,550 5 mg (Period B) | Placebo for 5 mg CP-690,550 (Period B) | CP-690,550 10 mg (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Week 4 | 100.0 (100.0 to 100.0) | 90.0 (81.0 to 94.9) | 100.0 (100.0 to 100.0) | 85.9 (78.6 to 90.9) |
| Week 8 | 96.7 (78.6 to 99.5) | 72.0 (60.6 to 80.6) | 97.7 (84.6 to 99.7) | 68.4 (59.5 to 75.7) |
| Week 12 | 96.7 (78.6 to 99.5) | 58.8 (47.0 to 68.8) | 93.0 (79.9 to 97.7) | 58.5 (49.4 to 66.6) |
| Week 16 | 92.3 (72.1 to 98.0) | 32.8 (16.3 to 50.4) | 93.0 (79.9 to 97.7) | 42.9 (30.5 to 54.6) |
Adequate response defined as \>50% reduction of the Visit A4/Week 24 (last visit in Period A) PASI response.
| weeks | CP-690,550 5 mg (Period B) | Placebo for 5 mg CP-690,550 (Period B) | CP-690,550 10 mg (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Median Time to Loss of Adequate Response During the Double-Blind Treatment Withdrawal (Period B) | NA (NA to NA) | 16.4 (12.6 to NA) | NA (NA to NA) | 16.1 (14.1 to NA) |
The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI responses at each period are relative to Baseline-A where Baseline-A was defined as the last observation up to first dosing date in Period A. Weeks 4 and 8 are relative to the Period B baseline and are the same as Weeks 28 and 32, which are relative to Period A baseline. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.
| percentage of participants | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 (Period B) | CP-690,550 10 mg (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Week 4 (n=30,82,43,128) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Week 8 (n=31,70,43,106) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Overall (n=31,82,44,132) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI responses at each period are relative to Baseline-A where Baseline-A was defined as the last observation up to first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.
| percentage of participants | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 (Period B) | CP-690,550 10 mg (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Week 4 (n=30,82,43,128) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Week 8 (n=31,70,43,106) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Week 12 (n=30,53,43,87) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 1.15 (-3.39 to 1.09) |
| Week 16 (n=28,45,38,72) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Overall (n=31,82,45,132) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.76 (0.00 to 0.00) |
Adequate PASI response defined as less than or equal to 50% reduction of the Visit A4/Week 24 PASI Response.
| percentage of participants | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Week 4 | 100.00 (100.0 to 100.0) | 90.0 (81.0 to 94.9) | 100.0 (100.0 to 100.0) | 85.9 (78.6 to 90.9) |
| Week 8 | 96.7 (78.6 to 99.5) | 72.0 (60.6 to 80.6) | 97.7 (84.6 to 99.7) | 68.4 (59.5 to 75.7) |
| Week 12 | 96.7 (78.6 to 99.5) | 58.8 (47.0 to 68.8) | 93.0 (79.9 to 97.7) | 58.4 (49.3 to 66.5) |
| Week 16 | 92.3 (72.1 to 98.0) | 32.8 (16.3 to 50.4) | 93.0 (79.9 to 97.7) | 43.5 (31.0 to 55.3) |
| weeks | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Median Time to Loss of >50% of the Visit A4/Week 24 PASI Response and Loss of PGA Response (Clear or Almost Clear) During the Double-Blind Treatment Withdrawal (Period B) | NA (NA to NA) | 16.4 (12.6 to NA) | NA (NA to NA) | 16.1 (14.1 to NA) |
PASI75 response defined as at least a 75% reduction in PASI relative to baseline.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Week 4 | 14.3 (2.1 to 66.6) | 7.7 (3.0 to 19.2) | 14.3 (2.1 to 66.6) | 37.0 (27.6 to 48.5) |
| Week 8 | 28.6 (8.0 to 74.2) | 32.3 (21.2 to 47.3) | 42.9 (16.3 to 82.8) | 48.5 (38.2 to 60.0) |
| Week 16 | 64.3 (22.0 to 98.6) | 100.0 (NA to NA) | 42.9 (16.3 to 82.8) | 57.2 (46.2 to 68.8) |
PASI75 response defined as at least a 75% reduction in PASI relative to baseline.
| weeks | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Median Time to Regain PASI75 and PGA Response (Clear or Almost Clear) During CP-690,550 Re-Treatment (Period C) Among Participants Who Lost Both PASI75 Response and PGA Response (Clear or Almost Clear) at the Beginning of Period C | 16.4 (8.6 to NA) | 16.4 (16.1 to 17.3) | NA (NA to NA) | 12.4 (7.6 to NA) |
PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses at each period are relative to Baseline-A, where Baseline-A is defined as the last observation up to first dosing date in Period A. 95% confidence interval constructed using the normal approximation to the binomial distribution of one-sample proportion.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Week 4 | 14.29 (0.00 to 40.21) | 7.69 (0.45 to 14.93) | 14.29 (0.00 to 40.21) | 37.04 (26.52 to 47.55) |
| Week 8 | 28.57 (0.00 to 62.04) | 28.85 (16.53 to 41.16) | 42.86 (6.2 to 79.52) | 41.98 (31.23 to 52.72) |
| Week 16 | 28.57 (0.00 to 62.04) | 21.15 (10.05 to 32.25) | 42.86 (6.20 to 79.52) | 41.98 (31.23 to 52.72) |
PASI75 response defined as at least a 75% reduction in PASI relative to baseline.
| weeks | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Median Time to PASI75 Response During CP-690,550 Re-Treatment (Period C) For Those Who Had a >50% Reduction of Visit A4/Week 24 PASI Response During Double-Blind Treatment Withdrawal (Period B) | 4.5 (4.3 to 4.7) | 16.4 (16.1 to 17.3) | NA (NA to NA) | 8.1 (5.9 to 16.1) |
| weeks | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Median Time to PGA Response of Clear or Almost Clear During CP-690,550 Re-Treatment (Period C) Among Participants Who Had a PGA of Mild, Moderate, or Severe at the Beginning of Period C | 16.3 (16.1 to 16.4) | 16.1 (8.4 to 16.6) | 13.1 (6.0 to NA) | 8.1 (5.0 to 16.1) |
PASI75 response defined as at least a 75% reduction in PASI relative to baseline. Baseline defined as the last observation up to the first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.
| percentage of participants | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 | 7.85 (4.96 to 10.75) | 22.39 (17.92 to 26.85) |
| Week 8 | 23.87 (19.27 to 28.46) | 50.45 (45.09 to 55.80) |
| Week 16 | 38.07 (32.84 to 43.30) | 60.60 (55.36 to 65.83) |
| Week 24 | 38.97 (33.72 to 44.23) | 59.40 (54.14 to 64.66) |
PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses in each period are relative to Baseline-A, where Baseline-A is defined as the last observation until first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.
| percentage of participants | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Week 4 | 87.10 (7.94 to 39.43) | 63.41 (0.00 to 0.00) | 86.67 (14.29 to 40.24) | 59.40 (0.00 to 0.00) |
| Week 8 | 70.97 (17.83 to 55.81) | 34.15 (0.00 to 0.00) | 86.67 (35.40 to 61.24) | 38.35 (0.00 to 0.00) |
| Week 12 | 67.74 (18.02 to 56.49) | 30.49 (0.00 to 0.00) | 77.78 (29.38 to 58.51) | 33.83 (0.00 to 0.00) |
| Week 16 | 64.52 (20.89 to 59.36) | 24.39 (0.00 to 0.00) | 62.22 (18.32 to 50.49) | 27.82 (0.00 to 0.00) |
PASI75 response defined as at least a 75% reduction in PASI relative to baseline. PASI responses in each period are relative to Baseline-A, where Baseline-A is defined as the last observation until first dosing date in Period A. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Week 4 | 70.37 (53.15 to 87.59) | 34.67 (23.90 to 45.44) | 73.81 (60.51 to 87.11) | 60.83 (52.10 to 69.57) |
| Week 8 | 62.96 (44.75 to 81.18) | 48.00 (36.69 to 59.31) | 66.67 (52.41 to 80.92) | 68.33 (60.01 to 76.66) |
| Week 16 | 55.56 (36.81 to 74.30) | 45.33 (34.07 to 56.60) | 69.05 (55.07 to 83.03) | 61.67 (52.97 to 70.37) |
PGA response was defined as 0 (clear) or 1 (almost clear) on a 5-point scale where 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.
| percentage of participants | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 | 14.20 (10.44 to 17.96) | 37.91 (32.72 to 43.11) |
| Week 8 | 30.51 (25.55 to 35.47) | 54.03 (48.69 to 59.37) |
| Week 16 | 37.16 (31.95 to 42.37) | 58.81 (53.54 to 64.08) |
| Week 24 | 37.16 (31.95 to 42.37) | 55.22 (49.90 to 60.55) |
PGA response was defined as 0 (clear) or 1 (almost clear) on a 5-point scale where 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. 95% confidence interval is constructed using the normal approximation to the binomial distribution of two-sample proportion.
| percentage of participants | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Week 4 | 77.42 (1.90 to 38.30) | 57.32 (0.00 to 0.00) | 77.78 (14.84 to 44.48) | 48.12 (0.00 to 0.00) |
| Week 8 | 74.19 (22.81 to 59.73) | 32.93 (0.00 to 0.00) | 82.22 (35.40 to 62.88) | 33.08 (0.00 to 0.00) |
| Week 12 | 70.97 (24.21 to 61.62) | 28.05 (0.00 to 0.00) | 66.67 (24.68 to 56.09) | 26.32 (0.00 to 0.00) |
| Week 16 | 58.06 (10.11 to 49.92) | 28.05 (0.00 to 0.00) | 62.22 (25.40 to 56.94) | 21.05 (0.00 to 0.00) |
PGA response was defined as 0 (clear) or 1 (almost clear) on a 5-point scale where 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. 95% confidence interval is constructed using the normal approximation to the binomial distribution of one-sample proportion.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Week 4 | 62.96 (44.75 to 81.18) | 40.00 (28.91 to 51.09) | 61.90 (47.22 to 76.59) | 59.17 (50.37 to 67.96) |
| Week 8 | 62.96 (44.75 to 81.18) | 49.33 (38.02 to 60.65) | 54.76 (39.71 to 69.81) | 63.33 (54.71 to 71.96) |
| Week 16 | 55.56 (36.81 to 74.30) | 49.33 (38.02 to 60.65) | 59.52 (44.68 to 74.37) | 55.00 (46.10 to 63.90) |
Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
| percent psoriatic BSA | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Baseline (n=331,335) | 27.5 ± 0.9 | 27.2 ± 0.9 |
| Week 4 (n=326,331) | 22.3 ± 0.9 | 18.1 ± 0.8 |
| Week 8 (n=322,323) | 17.2 ± 0.9 | 12.1 ± 0.8 |
| Week 16 (n=311,306) | 13.3 ± 0.8 | 8.1 ± 0.7 |
| Week 24 (n=277,279) | 12.0 ± 0.8 | 6.4 ± 0.7 |
Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
| percent psoriatic BSA | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Baseline (n=31,82,45,133) | 1.9 ± 0.4 | 3.8 ± 0.8 | 2.0 ± 0.3 | 2.7 ± 0.4 |
| Week 4 (n=30,82,43,128) | 1.9 ± 0.4 | 6.1 ± 0.8 | 1.8 ± 0.4 | 6.8 ± 0.9 |
| Week 8 (n=30,70,43,104) | 2.2 ± 0.4 | 7.7 ± 1.2 | 2.0 ± 0.4 | 8.7 ± 1.2 |
| Week 12 (n=28,53,42,84) | 2.0 ± 0.4 | 7.2 ± 1.0 | 2.3 ± 0.5 | 6.2 ± 0.9 |
| Week 16 (n=28,45,38,70) | 2.2 ± 0.5 | 6.0 ± 0.9 | 2.6 ± 0.7 | 6.0 ± 0.8 |
Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
| percent psoriatic BSA | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline (n=27,75,42,120) | 2.3 ± 0.5 | 11.4 ± 1.3 | 3.0 ± 0.8 | 12.0 ± 1.2 |
| Week 4 (n=27,74,42,119) | 2.1 ± 0.4 | 10.6 ± 1.7 | 3.1 ± 0.9 | 7.2 ± 0.9 |
| Week 8 (n=26,72,41,118) | 2.5 ± 0.5 | 9.0 ± 1.6 | 3.3 ± 1.0 | 6.1 ± 0.8 |
| Week 16 (n=23,67,39,101) | 2.9 ± 0.5 | 7.1 ± 1.2 | 3.7 ± 1.3 | 4.5 ± 0.8 |
Baseline defined as the last observation up to first dosing date in Period A.
| percent change in psoriatic BSA | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 (n=326,331) | -5.3 ± 0.5 | -9.0 ± 0.7 |
| Week 8 (n=322,323) | -10.4 ± 0.7 | -14.5 ± 0.8 |
| Week 16 (n=311,306) | -14.4 ± 0.8 | -18.5 ± 0.9 |
| Week 24 (n=277,279) | -15.2 ± 0.9 | -19.4 ± 0.9 |
Baseline defined as the last observation up to first dosing date in Period B.
| percent change in psoriatic BSA | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Week 4 (n=30,82,43,128) | 0.0 ± 0.4 | 2.3 ± 0.9 | -0.3 ± 0.3 | 4.1 ± 0.6 |
| Week 8 (n=30,70,43,104) | 0.3 ± 0.4 | 4.1 ± 0.9 | -0.1 ± 0.4 | 6.3 ± 0.9 |
| Week 12 (n=28,53,42,84) | 0.1 ± 0.5 | 4.8 ± 1.0 | 0.3 ± 0.6 | 4.7 ± 0.7 |
| Week 16 (n=28,45,38,70) | 0.3 ± 0.5 | 3.7 ± 0.7 | 0.5 ± 0.7 | 4.5 ± 0.7 |
Baseline was defined as the last observation until first dosing date in Period C.
| percent change in psoriatic BSA | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Week 4 (n=27,74,42,119) | -0.2 ± 0.3 | -1.0 ± 1.0 | 0.1 ± 0.9 | -4.9 ± 0.8 |
| Week 8 (n=26,72,41,118) | 0.1 ± 0.5 | -2.3 ± 1.0 | 0.3 ± 0.9 | -5.5 ± 0.8 |
| Week 16 (n=23,67,39,101) | 0.5 ± 0.6 | -4.0 ± 1.1 | 0.6 ± 1.2 | -6.8 ± 0.8 |
Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
| percent psoriatic BSA | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Head/Neck, Baseline (n=331,335) | 28.7 ± 1.25 | 25.9 ± 1.17 |
| Head/Neck, Week 4 (n=326,331) | 20.5 ± 1.20 | 14.3 ± 1.04 |
| Head/Neck, Week 8 (n=322,323) | 14.8 ± 1.06 | 9.7 ± 0.96 |
| Head/Neck, Week 16 (n=311,306) | 12.6 ± 1.05 | 7.5 ± 0.88 |
| Head/Neck, Week 24 (n=277,279) | 12.8 ± 1.17 | 6.3 ± 0.89 |
| Upper limbs, Baseline (n=331,335) | 26.5 ± 1.04 | 26.2 ± 1.06 |
| Upper limbs, Week 4 (n=326,331) | 21.8 ± 1.02 | 17.3 ± 0.91 |
| Upper limbs, Week 8 (n=322,323) | 17.0 ± 0.95 | 11.7 ± 0.83 |
| Upper Limbs, Week 16 (n=311,306) | 13.6 ± 0.92 | 8.0 ± 0.70 |
| Upper limbs, Week 24 (n=277,279) | 12.2 ± 0.98 | 6.5 ± 0.65 |
| Trunk, Baseline (n=331,335) | 26.0 ± 1.23 | 25.9 ± 1.18 |
| Trunk, Week 4 (n=326,331) | 20.8 ± 1.16 | 17.2 ± 1.02 |
| Trunk, Week 8 (n=322,323) | 16.5 ± 1.11 | 11.4 ± 0.94 |
| Trunk, Week 16 (n=311,306) | 13.5 ± 1.05 | 8.5 ± 0.95 |
| Trunk, Week 24 (n=277,279) | 12.5 ± 1.05 | 6.9 ± 0.85 |
| Lower limbs, Baseline (n=331,335) | 28.7 ± 1.14 | 28.9 ± 1.12 |
| Lower limbs, Week 4 (n=326,331) | 24.1 ± 1.13 | 20.2 ± 0.99 |
| Lower limbs, Week 8 (n=322,323) | 18.5 ± 1.05 | 13.4 ± 0.93 |
| Lower limbs, Week 16 (n=311,306) | 13.1 ± 0.95 | 7.9 ± 0.79 |
| Lower limbs, Week 24 (n=277,279) | 11.3 ± 0.90 | 6.1 ± 0.71 |
Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
| percent psoriatic BSA | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Head/Neck, Baseline (n=31,82,45,133) | 4.2 ± 1.53 | 3.3 ± 0.79 | 0.9 ± 0.34 | 2.8 ± 0.70 |
| Head/Neck, Week 4 (n=30,82,43,128) | 4.1 ± 1.44 | 11.3 ± 1.99 | 1.5 ± 0.44 | 12.2 ± 1.59 |
| Head/Neck, Week 8 (n=30,70,43,104) | 4.8 ± 1.80 | 13.0 ± 2.34 | 1.5 ± 0.46 | 15.1 ± 1.97 |
| Head/Neck, Week 12 (n=28,53,42,84) | 3.8 ± 1.00 | 13.5 ± 2.96 | 2.8 ± 0.72 | 11.5 ± 2.03 |
| Head/Neck, Week 16 (n=28,45,38,70) | 3.8 ± 1.19 | 9.2 ± 2.11 | 2.3 ± 0.80 | 9.6 ± 1.76 |
| Upper limbs, Baseline (n=31,82,45,133) | 2.1 ± 0.42 | 5.1 ± 1.00 | 3.1 ± 0.55 | 3.1 ± 0.50 |
| Upper limbs, Week 4 (n=30,82,43,128) | 2.4 ± 0.48 | 7.5 ± 1.19 | 3.0 ± 0.55 | 7.6 ± 0.97 |
| Upper limbs, Week 8 (n=30,70,43,104) | 2.8 ± 0.58 | 8.9 ± 1.41 | 3.6 ± 0.68 | 8.9 ± 1.25 |
| Upper limbs, Week 12 (n=28,53,42,84) | 3.1 ± 0.59 | 8.8 ± 1.38 | 3.3 ± 0.62 | 6.6 ± 1.00 |
| Upper limbs, Week 16 (n=28,45,38,70) | 3.2 ± 0.70 | 6.5 ± 1.13 | 3.5 ± 0.66 | 6.9 ± 1.28 |
| Trunk, Baseline (n=31,82,45,133) | 1.6 ± 0.52 | 3.2 ± 0.88 | 1.5 ± 0.53 | 2.6 ± 0.59 |
| Trunk, Week 4 (n=30,82,43,128) | 1.8 ± 0.53 | 5.1 ± 1.00 | 1.6 ± 0.53 | 6.0 ± 1.05 |
| Trunk, Week 8 (n=30,70,43,104) | 1.9 ± 0.56 | 7.4 ± 1.73 | 1.5 ± 0.37 | 7.9 ± 1.29 |
| Trunk, Week 12 (n=28,53,42,84) | 1.7 ± 0.61 | 4.4 ± 0.67 | 1.4 ± 0.39 | 5.3 ± 1.04 |
| Trunk, Week 16 (n=28,45,38,70) | 2.1 ± 0.74 | 4.8 ± 0.90 | 1.8 ± 0.91 | 5.5 ± 1.05 |
| Lower limbs, Baseline (n=31,82,45,133) | 1.3 ± 0.37 | 3.8 ± 1.02 | 2.1 ± 0.44 | 2.4 ± 0.49 |
| Lower limbs, Week 4 (n=30,82,43,128) | 1.2 ± 0.33 | 4.9 ± 0.75 | 1.4 ± 0.38 | 5.7 ± 0.90 |
| Lower limbs, Week 8 (n=30,70,43,104) | 1.5 ± 0.36 | 6.1 ± 1.07 | 1.7 ± 0.53 | 7.5 ± 1.30 |
| Lower limbs, Week 12 (n=28,53,42,84) | 1.2 ± 0.35 | 7.0 ± 1.24 | 2.4 ± 0.80 | 5.4 ± 0.95 |
| Lower limbs, Week 16 (n=28,45,38,70) | 1.4 ± 0.42 | 6.0 ± 1.30 | 3.0 ± 1.03 | 5.1 ± 0.78 |
Assessment of BSA with psoriasis performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The %surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis.
| percent psoriatic BSA | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Head/Neck, Baseline (n=27,75,42,120) | 4.0 ± 1.23 | 18.6 ± 2.62 | 2.0 ± 0.61 | 18.3 ± 1.95 |
| Head/Neck, Week 4 (n=27,74,42,119) | 3.6 ± 1.33 | 12.5 ± 2.09 | 2.9 ± 0.76 | 7.5 ± 1.12 |
| Head/Neck, Week 8 (n=26,72,41,118) | 3.9 ± 1.25 | 9.5 ± 2.01 | 3.3 ± 1.08 | 6.3 ± 1.02 |
| Head/Neck, Week 16 (n=23,67,39,101) | 4.6 ± 1.50 | 9.8 ± 1.97 | 1.4 ± 0.46 | 6.1 ± 1.31 |
| Upper limbs, Baseline (n=27,75,42,120) | 3.2 ± 0.72 | 12.5 ± 1.73 | 3.6 ± 0.63 | 13.2 ± 1.40 |
| Upper limbs, Week 4 (n=27,74,42,119) | 3.4 ± 0.82 | 11.1 ± 1.92 | 4.1 ± 0.90 | 8.4 ± 1.23 |
| Upper limbs, Week 8 (n=26,72,41,118) | 4.1 ± 0.99 | 8.9 ± 1.83 | 3.7 ± 0.92 | 6.7 ± 0.97 |
| Upper limbs, Week 16 (n=23,67,39,101) | 4.0 ± 1.02 | 7.0 ± 1.33 | 4.6 ± 1.24 | 5.3 ± 1.02 |
| Trunk, Baseline (n=27,75,42,120) | 2.2 ± 0.77 | 10.9 ± 1.73 | 2.0 ± 0.85 | 11.1 ± 1.35 |
| Trunk, Week 4 (n=27,74,42,119) | 2.0 ± 0.68 | 11.1 ± 2.33 | 3.2 ± 1.72 | 6.7 ± 1.10 |
| Trunk, Week 8 (n=26,72,41,118) | 2.4 ± 0.73 | 10.2 ± 2.16 | 3.5 ± 1.76 | 5.9 ± 1.15 |
| Trunk, Week 16 (n=23,67,39,101) | 3.0 ± 0.96 | 7.1 ± 1.54 | 4.7 ± 2.34 | 4.8 ± 1.16 |
| Lower limbs, Baseline (n=27,75,42,120) | 1.4 ± 0.44 | 9.4 ± 1.21 | 3.7 ± 1.15 | 10.4 ± 1.27 |
| Lower limbs, Week 4 (n=27,74,42,119) | 1.1 ± 0.27 | 9.5 ± 1.81 | 2.6 ± 0.95 | 6.9 ± 1.06 |
| Lower limbs, Week 8 (n=26,72,41,118) | 1.4 ± 0.38 | 8.0 ± 1.73 | 3.0 ± 1.10 | 5.8 ± 0.92 |
| Lower limbs, Week 16 (n=23,67,39,101) | 1.8 ± 0.45 | 6.5 ± 1.26 | 3.0 ± 1.33 | 3.5 ± 0.64 |
Baseline defined as the last observation up to first dosing date in Period A.
| percent change in psoriatic BSA | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Head/Neck, Week 4 (n=326,331) | -7.9 ± 0.71 | -11.7 ± 0.86 |
| Head/Neck, Week 8 (n=322,323) | -13.8 ± 0.98 | -16.0 ± 1.04 |
| Head/Neck, Week 16 (n=311,306) | -15.4 ± 1.13 | -17.9 ± 1.07 |
| Head/Neck, Week 24 (n=277,279) | -14.9 ± 1.21 | -18.6 ± 1.12 |
| Upper limbs, Week 4 (n=326,331) | -4.9 ± 0.58 | -8.8 ± 0.80 |
| Upper limbs, Week 8 (n=322,323) | -9.7 ± 0.77 | -14.1 ± 0.92 |
| Upper limbs, Week 16 (n=311,306) | -13.1 ± 0.89 | -17.4 ± 1.03 |
| Upper limbs, Week 24 (n=277,279) | -14.2 ± 0.98 | -18.5 ± 1.01 |
| Trunk, Week 4 (n=326,331) | -5.5 ± 0.67 | -8.6 ± 0.86 |
| Trunk, Week 8 (n=322,323) | -9.9 ± 0.87 | -13.8 ± 1.03 |
| Trunk, Week 16 (n=311,306) | -12.9 ± 0.98 | -16.9 ± 1.17 |
| Trunk, Week 24 (n=277,279) | -13.4 ± 1.12 | -17.8 ± 1.12 |
| Lower limbs, Week 4 (n=326,331) | -4.8 ± 0.57 | -8.6 ± 0.85 |
| Lower limbs, Week 8 (n=322,323) | -10.4 ± 0.82 | -14.8 ± 0.99 |
| Lower limbs, Week 16 (n=311,306) | -15.9 ± 1.04 | -20.3 ± 1.10 |
| Lower limbs, Week 24 (n=277,279) | -17.1 ± 1.09 | -21.2 ± 1.07 |
Baseline defined as the last observation up to first dosing date in Period B.
| percent psoriatic BSA | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Head/Neck, Week 4 (n=30,82,43,128) | -0.3 ± 0.98 | 8.0 ± 1.49 | 0.7 ± 0.44 | 9.3 ± 1.53 |
| Head/Neck, Week 8 (n=30,70,43,104) | 0.4 ± 1.41 | 10.0 ± 1.87 | 0.6 ± 0.50 | 12.8 ± 1.86 |
| Head/Neck, Week 12 (n=28,53,42,84) | -0.9 ± 1.58 | 11.8 ± 2.71 | 1.8 ± 0.69 | 10.4 ± 1.95 |
| Head/Neck, Week 16 (n=28,45,38,70) | -0.8 ± 1.42 | 7.9 ± 1.70 | 1.2 ± 0.75 | 8.3 ± 1.66 |
| Upper limbs, Week 4 (n=30,82,43,128) | 0.4 ± 0.33 | 2.3 ± 1.14 | -0.2 ± 0.29 | 4.5 ± 0.76 |
| Upper limbs, Week 8 (n=30,70,43,104) | 0.8 ± 0.47 | 4.1 ± 0.99 | 0.4 ± 0.54 | 6.2 ± 0.96 |
| Upper limbs, Week 12 (n=28,53,42,84) | 1.0 ± 0.51 | 4.8 ± 1.14 | 0.4 ± 0.50 | 4.7 ± 0.86 |
| Upper limbs, Week 16 (n=28,45,38,70) | 1.1 ± 0.55 | 2.7 ± 0.75 | 0.6 ± 0.46 | 4.9 ± 0.95 |
| Trunk, Week 4 (n=30,82,43,128) | 0.1 ± 0.50 | 1.9 ± 1.17 | 0.0 ± 0.51 | 3.3 ± 0.74 |
| Trunk, Week 8 (n=30,70,43,104) | 0.3 ± 0.54 | 4.0 ± 1.34 | -0.2 ± 0.56 | 5.6 ± 0.97 |
| Trunk, Week 12 (n=28,53,42,84) | 0.0 ± 0.68 | 2.9 ± 0.75 | -0.2 ± 0.63 | 3.8 ± 0.75 |
| Trunk, Week 16 (n=28,45,38,70) | 0.4 ± 0.73 | 3.3 ± 0.81 | 0.0 ± 1.09 | 3.9 ± 0.71 |
| Lower limbs, Week 4 (n=30,82,43,128) | -0.2 ± 0.42 | 1.1 ± 0.92 | -0.7 ± 0.39 | 3.2 ± 0.68 |
| Lower limbs, Week 8 (n=30,70,43,104) | 0.2 ± 0.43 | 2.7 ± 0.83 | -0.5 ± 0.66 | 5.3 ± 0.98 |
| Lower limbs, Week 12 (n=28,53,42,84) | -0.1 ± 0.47 | 4.6 ± 1.19 | 0.3 ± 0.84 | 3.9 ± 0.84 |
| Lower limbs, Week 16 (n=28,45,38,70) | 0.0 ± 0.51 | 3.3 ± 0.94 | 0.7 ± 0.86 | 3.7 ± 0.76 |
Baseline defined as the last observation up to first dosing date in Period C.
| percent psoriatic BSA | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Head/Neck, Week 4 (n=27,74,42,119) | -0.3 ± 0.92 | -6.4 ± 1.40 | 0.9 ± 0.81 | -10.8 ± 1.53 |
| Head/Neck, Week 8 (n=26,72,41,118) | 0.0 ± 1.07 | -8.6 ± 1.68 | 1.2 ± 0.91 | -10.9 ± 1.51 |
| Head/Neck, Week 16 (n=23,67,39,101) | 0.4 ± 1.41 | -8.1 ± 2.04 | -0.7 ± 0.77 | -11.6 ± 1.84 |
| Upper limbs, Week 4 (n=27,74,42,119) | 0.1 ± 0.26 | -1.6 ± 0.90 | 0.5 ± 0.69 | -4.9 ± 0.94 |
| Upper limbs, Week 8 (n=26,72,41,118) | 0.8 ± 0.50 | -3.0 ± 0.85 | 0.1 ± 0.53 | -6.3 ± 1.11 |
| Upper limbs, Week 16 (n=23,67,39,101) | 0.7 ± 0.97 | -5.0 ± 1.15 | 1.0 ± 0.99 | -7.6 ± 1.20 |
| Trunk, Week 4 (n=27,74,42,119) | -0.2 ± 0.20 | 0.1 ± 1.12 | 1.3 ± 1.87 | -4.6 ± 0.88 |
| Trunk, Week 8 (n=26,72,41,118) | 0.1 ± 0.43 | -1.1 ± 1.04 | 1.5 ± 1.92 | -4.8 ± 0.88 |
| Trunk, Week 16 (n=23,67,39,101) | 0.7 ± 0.82 | -4.1 ± 1.44 | 2.7 ± 2.46 | -5.6 ± 1.02 |
| Lower limbs, Week 4 (n=27,74,42,119) | -0.3 ± 0.36 | -0.1 ± 1.44 | -1.1 ± 0.93 | -3.6 ± 0.97 |
| Lower limbs, Week 8 (n=26,72,41,118) | -0.1 ± 0.52 | -1.3 ± 1.50 | -0.7 ± 0.78 | -4.3 ± 0.85 |
| Lower limbs, Week 16 (n=23,67,39,101) | 0.2 ± 0.60 | -2.3 ± 1.15 | -0.9 ± 1.14 | -6.1 ± 0.93 |
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis.
| score on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Baseline (n=331,335) | 21.1 ± 0.5 | 20.9 ± 0.4 |
| Week 4 (n=326,331) | 13.5 ± 0.5 | 10.4 ± 0.4 |
| Week 8 (n=322,323) | 10.1 ± 0.4 | 6.5 ± 0.4 |
| Week 16 (n=311,307) | 8.1 ± 0.4 | 5.0 ± 0.4 |
| Week 24 (n=277,279) | 7.6 ± 0.4 | 4.4 ± 0.4 |
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.
| score on a scale | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Baseline (n=31,82,45,133) | 1.6 ± 0.2 | 1.8 ± 0.2 | 1.7 ± 0.2 | 1.5 ± 0.1 |
| Week 4 (n=30,82,43,128) | 2.0 ± 0.3 | 5.0 ± 0.6 | 1.8 ± 0.3 | 5.3 ± 0.6 |
| Week 8 (n=30,70,43,104) | 2.4 ± 0.4 | 6.5 ± 0.7 | 2.0 ± 0.4 | 6.8 ± 0.7 |
| Week 12 (n=28,53,42,84) | 2.3 ± 0.4 | 6.4 ± 0.7 | 2.5 ± 0.4 | 5.6 ± 0.6 |
| Week 16 (n=28,45,38,70) | 2.7 ± 0.5 | 5.5 ± 0.7 | 2.9 ± 0.5 | 5.5 ± 0.6 |
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.
| score on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline (n=27,75,42,120) | 2.7 ± 0.5 | 9.9 ± 0.9 | 3.4 ± 0.6 | 9.8 ± 0.8 |
| Week 4 (n=27,74,42,119) | 2.5 ± 0.4 | 7.8 ± 1.0 | 3.3 ± 0.6 | 5.0 ± 0.5 |
| Week 8 (n=26,72,41,118) | 2.6 ± 0.5 | 6.0 ± 0.9 | 3.2 ± 0.6 | 4.1 ± 0.5 |
| Week 16 (n=23,67,39,101) | 2.9 ± 0.5 | 5.2 ± 0.8 | 3.5 ± 0.7 | 3.5 ± 0.5 |
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
| scores on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 (n=326,331) | -7.6 ± 0.4 | -10.5 ± 0.4 |
| Week 8 (n=322,323) | -11.1 ± 0.4 | -14.2 ± 0.5 |
| Week 16 (n=311,307) | -13.1 ± 0.5 | -15.8 ± 0.5 |
| Week 24 (n=277,279) | -13.4 ± 0.5 | -16.0 ± 0.5 |
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-B defined as last observation up to first dosing date in Period B.
| scores on a scale | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Week 4 (n=30,82,43,128) | 0.4 ± 0.2 | 3.3 ± 0.6 | 0.2 ± 0.2 | 3.8 ± 0.5 |
| Week 8 (n=30,70,43,104) | 0.9 ± 0.4 | 4.9 ± 0.7 | 0.3 ± 0.3 | 5.4 ± 0.6 |
| Week 12 (n=28,53,42,84) | 0.7 ± 0.4 | 4.8 ± 0.7 | 0.9 ± 0.4 | 4.5 ± 0.6 |
| Week 16 (n=28,45,38,70) | 1.0 ± 0.5 | 4.1 ± 0.6 | 1.4 ± 0.4 | 4.4 ± 0.5 |
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline-C defined as last observation up to first dosing date in Period C.
| scores on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Week 4 (n=27,74,42,119) | -0.2 ± 0.4 | -2.3 ± 0.7 | -0.1 ± 0.5 | -4.8 ± 0.6 |
| Week 8 (n=26,72,41,118) | 0.0 ± 0.5 | -3.8 ± 0.7 | -0.2 ± 0.4 | -5.4 ± 0.6 |
| Week 16 (n=23,67,39,101) | 0.1 ± 0.6 | -4.5 ± 0.9 | -0.0 ± 0.7 | -5.9 ± 0.6 |
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.
| score on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Erythema Head/Neck, Baseline (n=331,335) | 2.2 ± 0.1 | 2.2 ± 0.1 |
| Erythema Head/Neck, Week 4 (n=326,331) | 1.4 ± 0.1 | 1.1 ± 0.1 |
| Erythema Head/Neck, Week 8 (n=322,323) | 1.1 ± 0.1 | 0.7 ± 0.0 |
| Erythema Head/Neck, Week 16 (n=311,307) | 1.0 ± 0.1 | 0.7 ± 0.1 |
| Erythema Head/Neck, Week 24 (n=277,279) | 1.0 ± 0.1 | 0.6 ± 0.1 |
| Induration Head/Neck, Baseline (n=331,335) | 2.0 ± 0.1 | 1.9 ± 0.1 |
| Induration Head/Neck, Week 4 (n=326,331) | 1.2 ± 0.1 | 0.9 ± 0.1 |
| Induration Head/Neck, Week 8 (n=322,323) | 0.9 ± 0.1 | 0.6 ± 0.0 |
| Induration Head/Neck, Week 16 (n=311,307) | 0.8 ± 0.1 | 0.5 ± 0.0 |
| Induration Head/Neck, Week 24 (n=277,279) | 0.8 ± 0.1 | 0.5 ± 0.0 |
| Scaling Head/Neck, Baseline (n=331,335) | 2.2 ± 0.1 | 2.1 ± 0.1 |
| Scaling Head/Neck, Week 4 (n=326,331) | 1.3 ± 0.1 | 1.0 ± 0.1 |
| Scaling Head/Neck, Week 8 (n=322,323) | 1.0 ± 0.1 | 0.6 ± 0.0 |
| Scaling Head/Neck, Week 16 (n=311,307) | 0.9 ± 0.1 | 0.6 ± 0.1 |
| Scaling Head/Neck, Week 24 (n=277,279) | 0.9 ± 0.1 | 0.6 ± 0.1 |
| Erythema Upper limbs, Baseline (n=331,335) | 2.8 ± 0.0 | 2.8 ± 0.0 |
| Erythema Upper limbs, Week 4 (n=326,331) | 1.9 ± 0.0 | 1.6 ± 0.0 |
| Erythema Upper limbs, Week 8 (n=322,323) | 1.6 ± 0.1 | 1.2 ± 0.0 |
| Erythema Upper limbs, Week 16 (n=311,307) | 1.4 ± 0.1 | 1.1 ± 0.1 |
| Erythema Upper limbs, Week 24 (n=277,279) | 1.4 ± 0.1 | 1.0 ± 0.1 |
| Induration Upper limbs, Baseline (n=331,335) | 2.6 ± 0.0 | 2.6 ± 0.0 |
| Induration Upper limbs, Week 4 (n=326,331) | 1.9 ± 0.0 | 1.5 ± 0.1 |
| Induration Upper limbs, Week 8 (n=322,323) | 1.5 ± 0.1 | 1.1 ± 0.1 |
| Induration Upper limbs, Week 16 (n=311,307 | 1.4 ± 0.1 | 1.0 ± 0.1 |
| Induration Upper limbs, Week 24 (n=277,279) | 1.4 ± 0.1 | 1.0 ± 0.1 |
| Scaling Upper limbs, Baseline (n=331,335) | 2.7 ± 0.0 | 2.6 ± 0.0 |
| Scaling Upper limbs, Week 4 (n=326,331) | 1.9 ± 0.0 | 1.5 ± 0.1 |
| Scaling Upper limbs, Week 8 (n=322,323) | 1.5 ± 0.1 | 1.1 ± 0.1 |
| Scaling Upper limbs, Week 16 (n=311,307) | 1.4 ± 0.1 | 1.0 ± 0.1 |
| Scaling Upper limbs, Week 24 (n=277,279) | 1.4 ± 0.1 | 1.0 ± 0.1 |
| Erythema Trunk, Baseline (n=331,335) | 2.9 ± 0.0 | 2.8 ± 0.0 |
| Erythema Trunk, Week 4 (n=326,331) | 1.9 ± 0.1 | 1.6 ± 0.1 |
| Erythema Trunk, Week 8 (n=322,323) | 1.6 ± 0.1 | 1.1 ± 0.1 |
| Erythema Trunk, Week 16 (n=311,307) | 1.4 ± 0.1 | 0.9 ± 0.1 |
| Erythema Trunk, Week 24 (n=277,279) | 1.4 ± 0.1 | 0.8 ± 0.1 |
| Induration Trunk, Baseline (n=331,335) | 2.6 ± 0.0 | 2.6 ± 0.0 |
| Induration Trunk, Week 4 (n=326,331) | 1.8 ± 0.1 | 1.4 ± 0.1 |
| Induration Trunk, Week 8 (n=322,323) | 1.4 ± 0.1 | 0.9 ± 0.1 |
| Induration Trunk, Week 16 (n=311,307) | 1.2 ± 0.1 | 0.8 ± 0.1 |
| Induration Trunk, Week 24 (n=277,279) | 1.2 ± 0.1 | 0.7 ± 0.1 |
| Scaling Trunk, Baseline (n=331,335) | 2.6 ± 0.0 | 2.5 ± 0.0 |
| Scaling Trunk, Week 4 (n=326,331) | 1.7 ± 0.1 | 1.4 ± 0.1 |
| Scaling Trunk, Week 8 (n=322,323) | 1.3 ± 0.1 | 0.9 ± 0.1 |
| Scaling Trunk, Week 16 (n=311,307) | 1.2 ± 0.1 | 0.7 ± 0.1 |
| Scaling Trunk, Week 24 (n=277,279) | 1.1 ± 0.1 | 0.7 ± 0.1 |
| Erythema Lower limbs, Baseline (n=331,335) | 3.1 ± 0.0 | 3.1 ± 0.0 |
| Erythema Lower limbs, Week 4 (n=326,331) | 2.2 ± 0.0 | 1.9 ± 0.1 |
| Erythema Lower limbs, Week 8 (n=322,323) | 1.9 ± 0.1 | 1.4 ± 0.1 |
| Erythema Lower limbs, Week 16 (n=311,307) | 1.5 ± 0.1 | 1.1 ± 0.1 |
| Erythema Lower limbs, Week 24 (n=277,279) | 1.4 ± 0.1 | 1.0 ± 0.1 |
| Induration Lower limbs, Baseline (n=331,335) | 2.9 ± 0.0 | 2.9 ± 0.0 |
| Induration Lower limbs, Week 4 (n=326,331) | 2.1 ± 0.0 | 1.6 ± 0.1 |
| Induration Lwer limbs, Week 8 (n=322,323) | 1.6 ± 0.1 | 1.2 ± 0.1 |
| Induration Lower limbs, Week 16 (n=311,307) | 1.3 ± 0.1 | 0.9 ± 0.1 |
| Induration Lower limbs, Week 24 (n=277,279) | 1.3 ± 0.1 | 0.9 ± 0.1 |
| Scaling Lower limbs, Baseline (n=331,335) | 2.9 ± 0.0 | 2.9 ± 0.0 |
| Scaling Lower limbs, Week 4 (n=326,331) | 2.0 ± 0.1 | 1.8 ± 0.1 |
| Scaling Lower limbs, Week 8 (n=322,323) | 1.6 ± 0.1 | 1.2 ± 0.1 |
| Scaling Lower limbs, Week 16 (n=311,307) | 1.3 ± 0.1 | 1.0 ± 0.1 |
| Scaling Lower limbs, Week 24 (n=277,279) | 1.3 ± 0.1 | 1.0 ± 0.1 |
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.
| score on a scale | CP-690,550 5 mg BID (Period B) | Placebo for CP-690,550 5 mg BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 (Period B) |
|---|---|---|---|---|
| Erythema Head/Neck, Baseline (n=31,82,45,133) | 0.5 ± 0.1 | 0.4 ± 0.1 | 0.3 ± 0.1 | 0.3 ± 0.0 |
| Erythema Head/Neck, Week 4 (n=30,82,43,128) | 0.6 ± 0.1 | 1.1 ± 0.1 | 0.4 ± 0.1 | 1.1 ± 0.1 |
| Erythema Head/Neck, Week 8 (n=30,70,43,104) | 0.7 ± 0.2 | 1.2 ± 0.1 | 0.3 ± 0.1 | 1.3 ± 0.1 |
| Erythema Head/Neck, Week 12 (n=28,53,42,84) | 0.7 ± 0.2 | 1.1 ± 0.2 | 0.5 ± 0.1 | 1.1 ± 0.1 |
| Erythema Head/Neck, Week 16 (n=28,45,38,70) | 0.7 ± 0.2 | 0.8 ± 0.1 | 0.5 ± 0.1 | 1.0 ± 0.1 |
| Induration Head/Neck, Baseline (n=31,82,45,133) | 0.3 ± 0.1 | 0.4 ± 0.1 | 0.1 ± 0.1 | 0.2 ± 0.0 |
| Induration Head/Neck, Week 4 (n=30,82,43,128) | 0.4 ± 0.1 | 0.9 ± 0.1 | 0.3 ± 0.1 | 0.9 ± 0.1 |
| Induration Head/Neck, Week 8 (n=30,70,43,104) | 0.4 ± 0.1 | 1.0 ± 0.1 | 0.3 ± 0.1 | 1.1 ± 0.1 |
| Induration Head/Neck, Week 12 (n=28,53,42,84) | 0.4 ± 0.1 | 0.9 ± 0.1 | 0.4 ± 0.1 | 0.9 ± 0.1 |
| Induration Head/Neck, Week 16 (n=28,45,38,70) | 0.5 ± 0.1 | 0.7 ± 0.1 | 0.3 ± 0.1 | 0.8 ± 0.1 |
| Scaling Head/Neck, Baseline (n=31,82,45,133) | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.2 ± 0.1 | 0.3 ± 0.1 |
| Scaling Head/Neck, Week 4 (n=30,82,43,128) | 0.4 ± 0.1 | 1.0 ± 0.1 | 0.3 ± 0.1 | 1.1 ± 0.1 |
| Scaling Head/Neck, Week 8 (n=30,70,43,104) | 0.5 ± 0.1 | 1.1 ± 0.1 | 0.4 ± 0.1 | 1.3 ± 0.1 |
| Scaling Head/Neck, Week 12 (n=28,53,42,84) | 0.6 ± 0.1 | 1.1 ± 0.1 | 0.5 ± 0.1 | 1.1 ± 0.1 |
| Scaling Head/Neck, Week 16 (n=28,45,38,70) | 0.6 ± 0.2 | 0.8 ± 0.1 | 0.5 ± 0.1 | 0.9 ± 0.1 |
| Erythema Upper limbs, Baseline (n=31,82,45,133) | 0.6 ± 0.1 | 0.6 ± 0.1 | 0.8 ± 0.1 | 0.5 ± 0.1 |
| Erythema Upper limbs, Week 4 (n=30,82,43,128) | 0.8 ± 0.1 | 1.3 ± 0.1 | 0.8 ± 0.1 | 1.3 ± 0.1 |
| Erythema Upper limbs, Week 8 (n=30,70,43,104) | 0.9 ± 0.2 | 1.5 ± 0.1 | 0.9 ± 0.1 | 1.4 ± 0.1 |
| Erythema Upper limbs, Week 12 (n=28,53,42,84) | 1.0 ± 0.2 | 1.5 ± 0.1 | 0.9 ± 0.1 | 1.3 ± 0.1 |
| Erythema Upper limbs, Week 16 (n=28,45,38,70) | 1.0 ± 0.2 | 1.4 ± 0.1 | 1.1 ± 0.1 | 1.3 ± 0.1 |
| Induration Upper limbs, Baseline (n=31,82,45,133) | 0.7 ± 0.1 | 0.6 ± 0.1 | 0.6 ± 0.1 | 0.5 ± 0.1 |
| Induration Upper limbs, Week 4 (n=30,82,43,128) | 0.8 ± 0.1 | 1.3 ± 0.1 | 0.7 ± 0.1 | 1.1 ± 0.1 |
| Induration Upper limbs, Week 8 (n=30,70,43,104) | 0.8 ± 0.2 | 1.5 ± 0.1 | 0.8 ± 0.1 | 1.4 ± 0.1 |
| Induration Upper limbs, Week 12 (n=28,53,42,84) | 1.0 ± 0.2 | 1.5 ± 0.1 | 1.0 ± 0.1 | 1.3 ± 0.1 |
| Induration Upper limbs, Week 16 (n=28,45,38,70) | 1.1 ± 0.2 | 1.3 ± 0.2 | 1.1 ± 0.1 | 1.4 ± 0.1 |
| Scaling Upper limbs, Baseline (n=31,82,45,133) | 0.8 ± 0.2 | 0.6 ± 0.1 | 0.7 ± 0.1 | 0.5 ± 0.1 |
| Scaling Upper limbs, Week 4 (n=30,82,43,128) | 0.8 ± 0.2 | 1.3 ± 0.1 | 0.7 ± 0.1 | 1.2 ± 0.1 |
| Scaling Upper limbs, Week 8 (n=30,70,43,104) | 0.9 ± 0.2 | 1.4 ± 0.1 | 0.8 ± 0.1 | 1.4 ± 0.1 |
| Scaling Upper limbs, Week 12 (n=28,53,42,84) | 1.0 ± 0.2 | 1.4 ± 0.1 | 1.0 ± 0.1 | 1.4 ± 0.1 |
| Scaling Upper limbs, Week 16 (n=28,45,38,70) | 1.1 ± 0.2 | 1.3 ± 0.2 | 1.3 ± 0.2 | 1.4 ± 0.1 |
| Erythema Trunk, Baseline (n=31,82,45,133) | 0.5 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 |
| Erythema Trunk, Week 4 (n=30,82,43,128) | 0.7 ± 0.2 | 1.1 ± 0.1 | 0.4 ± 0.1 | 1.1 ± 0.1 |
| Erythema Trunk, Week 8 (n=30,70,43,104) | 0.9 ± 0.2 | 1.5 ± 0.1 | 0.5 ± 0.1 | 1.4 ± 0.1 |
| Erythema Trunk, Week 12 (n=28,53,42,84) | 0.7 ± 0.2 | 1.5 ± 0.2 | 0.5 ± 0.1 | 1.1 ± 0.1 |
| Erythema Trunk, Week 16 (n=28,45,38,70) | 0.9 ± 0.2 | 1.3 ± 0.2 | 0.5 ± 0.1 | 1.1 ± 0.1 |
| Induration Trunk, Baseline (n=31,82,45,133) | 0.4 ± 0.1 | 0.3 ± 0.1 | 0.3 ± 0.1 | 0.3 ± 0.0 |
| Induration Trunk, Week 4 (n=30,82,43,128) | 0.4 ± 0.1 | 0.9 ± 0.1 | 0.3 ± 0.1 | 0.8 ± 0.1 |
| Induration Trunk, Week 8 (n=30,70,43,104) | 0.5 ± 0.1 | 1.2 ± 0.1 | 0.4 ± 0.1 | 1.1 ± 0.1 |
| Induration Trunk, Week 12 (n=28,53,42,84) | 0.5 ± 0.2 | 1.2 ± 0.1 | 0.5 ± 0.1 | 0.9 ± 0.1 |
| Induration Trunk, Week 16 (n=28,45,38,70) | 0.6 ± 0.2 | 1.2 ± 0.2 | 0.6 ± 0.1 | 1.1 ± 0.1 |
| Scaling Trunk, Baseline (n=31,82,45,133) | 0.3 ± 0.1 | 0.3 ± 0.1 | 0.3 ± 0.1 | 0.3 ± 0.0 |
| Scaling Trunk, Week 4 (n=30,82,43,128) | 0.4 ± 0.1 | 0.9 ± 0.1 | 0.3 ± 0.1 | 0.8 ± 0.1 |
| Scaling Trunk, Week 8 (n=30,70,43,104) | 0.5 ± 0.1 | 1.2 ± 0.1 | 0.4 ± 0.1 | 1.1 ± 0.1 |
| Scaling Trunk, Week 12 (n=28,53,42,84) | 0.4 ± 0.1 | 1.2 ± 0.1 | 0.5 ± 0.1 | 0.9 ± 0.1 |
| Scaling Trunk, Week 16 (n=28,45,38,70) | 0.6 ± 0.2 | 1.1 ± 0.2 | 0.6 ± 0.1 | 1.0 ± 0.1 |
| Erythema Lower limbs, Baseline (n=31,82,45,133) | 0.5 ± 0.1 | 0.6 ± 0.1 | 0.8 ± 0.1 | 0.5 ± 0.1 |
| Erythema Lower limbs, Week 4 (n=30,82,43,128) | 0.6 ± 0.1 | 1.3 ± 0.1 | 0.8 ± 0.1 | 1.3 ± 0.1 |
| Erythema Lower limbs, Week 8 (n=30,70,43,104) | 0.8 ± 0.2 | 1.6 ± 0.1 | 0.8 ± 0.2 | 1.5 ± 0.1 |
| Erythema Lower limbs, Week 12 (n=28,53,42,84) | 0.8 ± 0.2 | 1.6 ± 0.2 | 0.9 ± 0.2 | 1.4 ± 0.1 |
| Erythema Lower limbs, Week 16 (n=28,45,38,70) | 0.8 ± 0.2 | 1.6 ± 0.2 | 1.0 ± 0.2 | 1.3 ± 0.1 |
| Induration Lower limbs, Baseline (n=31,82,45,133) | 0.5 ± 0.1 | 0.5 ± 0.1 | 0.6 ± 0.1 | 0.3 ± 0.0 |
| Induration Lower limbs, Week 4 (n=30,82,43,128) | 0.6 ± 0.1 | 1.0 ± 0.1 | 0.6 ± 0.1 | 1.0 ± 0.1 |
| Induration Lower limbs, Week 8 (n=30,70,43,104) | 0.6 ± 0.2 | 1.4 ± 0.1 | 0.6 ± 0.1 | 1.3 ± 0.1 |
| Induration Lower limbs, Week 12 (n=28,53,42,84) | 0.6 ± 0.2 | 1.4 ± 0.1 | 0.8 ± 0.1 | 1.2 ± 0.1 |
| Induration Lower limbs, Week 16 (n=28,45,38,70) | 0.6 ± 0.1 | 1.4 ± 0.2 | 0.9 ± 0.2 | 1.2 ± 0.1 |
| Scaling Lower limbs, Baseline (n=31,82,45,133) | 0.5 ± 0.1 | 0.4 ± 0.1 | 0.6 ± 0.1 | 0.4 ± 0.0 |
| Scaling Lower limbs, Week 4 (n=30,82,43,128) | 0.5 ± 0.1 | 1.0 ± 0.1 | 0.6 ± 0.1 | 1.0 ± 0.1 |
| Scaling Lower limbs, Week 8 (n=30,70,43,104) | 0.7 ± 0.2 | 1.3 ± 0.1 | 0.6 ± 0.1 | 1.3 ± 0.1 |
| Scaling Lower limbs, Week 12 (n=28,53,42,84) | 0.6 ± 0.2 | 1.4 ± 0.1 | 0.7 ± 0.1 | 1.3 ± 0.1 |
| Scaling Lower limbs, Week 16 (n=28,45,38,70) | 0.6 ± 0.2 | 1.4 ± 0.2 | 0.9 ± 0.2 | 1.3 ± 0.1 |
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.
| score on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Erythema Head/Neck, Baseline (n=27,75,42,120) | 0.7 ± 0.2 | 1.5 ± 0.1 | 0.5 ± 0.1 | 1.6 ± 0.1 |
| Erythema Head/Neck, Week 4 (n=27,74,42,119) | 0.6 ± 0.1 | 1.1 ± 0.1 | 0.6 ± 0.1 | 0.7 ± 0.1 |
| Erythema Head/Neck, Week 8 (n=26,72,41,118) | 0.8 ± 0.2 | 0.8 ± 0.1 | 0.5 ± 0.1 | 0.7 ± 0.1 |
| Erythema Head/Neck, Week 16 (n=23,67,39,101) | 0.7 ± 0.2 | 1.0 ± 0.1 | 0.4 ± 0.1 | 0.6 ± 0.1 |
| Induration Head/Neck, Baseline (n=27,75,42,120) | 0.5 ± 0.1 | 1.3 ± 0.1 | 0.4 ± 0.1 | 1.4 ± 0.1 |
| Induration Head/Neck, Week 4 (n=27,74,42,119) | 0.3 ± 0.1 | 0.9 ± 0.1 | 0.4 ± 0.1 | 0.6 ± 0.1 |
| Induration Head/Neck, Week 8 (n=26,72,41,118) | 0.4 ± 0.2 | 0.8 ± 0.1 | 0.3 ± 0.1 | 0.5 ± 0.1 |
| Induration Head/Neck, Week 16 (n=23,67,39,101) | 0.4 ± 0.1 | 0.7 ± 0.1 | 0.2 ± 0.1 | 0.5 ± 0.1 |
| Scaling Head/Neck, Baseline (n=27,75,42,120) | 0.6 ± 0.2 | 1.4 ± 0.1 | 0.5 ± 0.1 | 1.6 ± 0.1 |
| Scaling Head/Neck, Week 4 (n=27,74,42,119) | 0.5 ± 0.2 | 1.0 ± 0.1 | 0.6 ± 0.1 | 0.7 ± 0.1 |
| Scaling Head/Neck, Week 8 (n=26,72,41,118) | 0.7 ± 0.2 | 0.9 ± 0.1 | 0.5 ± 0.1 | 0.6 ± 0.1 |
| Scaling Head/Neck, Week 16 (n=23,67,39,101) | 0.5 ± 0.2 | 0.9 ± 0.1 | 0.4 ± 0.1 | 0.5 ± 0.1 |
| Erythema Upper limbs, Baseline (n=27,75,42,120) | 1.0 ± 0.2 | 1.9 ± 0.1 | 1.2 ± 0.2 | 1.8 ± 0.1 |
| Erythema Upper limbs, Week 4 (n=27,74,42,119) | 0.9 ± 0.2 | 1.5 ± 0.1 | 1.1 ± 0.2 | 1.1 ± 0.1 |
| Erythema Upper limbs, Week 8 (n=26,72,41,118) | 0.8 ± 0.2 | 1.2 ± 0.1 | 1.0 ± 0.1 | 1.0 ± 0.1 |
| Erythema Upper limbs, Week 16 (n=23,67,39,101) | 1.0 ± 0.2 | 1.3 ± 0.1 | 1.1 ± 0.2 | 0.9 ± 0.1 |
| Induration Upper limbs, Baseline (n=27,75,42,120) | 1.1 ± 0.2 | 1.9 ± 0.1 | 1.1 ± 0.1 | 1.7 ± 0.1 |
| Induration Upper limbs, Week 4 (n=27,74,42,119) | 1.0 ± 0.2 | 1.4 ± 0.1 | 1.1 ± 0.1 | 1.1 ± 0.1 |
| Induration Upper limbs, Week 8 (n=26,72,41,118) | 1.0 ± 0.2 | 1.2 ± 0.1 | 1.0 ± 0.1 | 1.0 ± 0.1 |
| Induration Upper limbs, Week 16 (n=23,67,39,101) | 1.1 ± 0.2 | 1.2 ± 0.1 | 1.1 ± 0.2 | 0.9 ± 0.1 |
| Scaling Upper limbs, Baseline (n=27,75,42,120) | 1.1 ± 0.2 | 1.8 ± 0.1 | 1.3 ± 0.2 | 1.8 ± 0.1 |
| Scaling Upper limbs, Week 4 (n=27,74,42,119) | 1.1 ± 0.2 | 1.5 ± 0.1 | 1.1 ± 0.1 | 1.1 ± 0.1 |
| Scaling Upper limbs, Week 8 (n=26,72,41,118) | 0.9 ± 0.2 | 1.2 ± 0.1 | 1.1 ± 0.1 | 1.0 ± 0.1 |
| Scaling Upper limbs, Week 16 (n=23,67,39,101) | 1.2 ± 0.2 | 1.3 ± 0.1 | 1.1 ± 0.2 | 0.9 ± 0.1 |
| Erythema Trunk, Baseline (n=27,75,42,120) | 0.9 ± 0.2 | 1.9 ± 0.1 | 0.7 ± 0.2 | 1.8 ± 0.1 |
| Erythema Trunk, Week 4 (n=27,74,42,119) | 0.8 ± 0.2 | 1.4 ± 0.1 | 0.6 ± 0.1 | 1.0 ± 0.1 |
| Erythema Trunk, Week 8 (n=26,72,41,118) | 0.8 ± 0.2 | 1.2 ± 0.1 | 0.7 ± 0.1 | 0.8 ± 0.1 |
| Erythema Trunk, Week 16 (n=23,67,39,101) | 0.7 ± 0.2 | 1.1 ± 0.1 | 0.6 ± 0.2 | 0.8 ± 0.1 |
| Induration Trunk, Baseline (n=27,75,42,120) | 0.7 ± 0.2 | 1.7 ± 0.1 | 0.7 ± 0.2 | 1.5 ± 0.1 |
| Induration Trunk, Week 4 (n=27,74,42,119) | 0.6 ± 0.2 | 1.2 ± 0.1 | 0.6 ± 0.1 | 0.8 ± 0.1 |
| Induration Trunk, Week 8 (n=26,72,41,118) | 0.5 ± 0.2 | 1.0 ± 0.1 | 0.6 ± 0.1 | 0.7 ± 0.1 |
| Induration Trunk, Week 16 (n=23,67,39,101) | 0.5 ± 0.2 | 0.9 ± 0.1 | 0.6 ± 0.1 | 0.7 ± 0.1 |
| Scaling Trunk, Baseline (n=27,75,42,120) | 0.7 ± 0.2 | 1.6 ± 0.1 | 0.7 ± 0.2 | 1.5 ± 0.1 |
| Scaling Trunk, Week 4 (n=27,74,42,119) | 0.5 ± 0.1 | 1.3 ± 0.1 | 0.6 ± 0.1 | 0.9 ± 0.1 |
| Scaling Trunk, Week 8 (n=26,72,41,118) | 0.5 ± 0.1 | 1.0 ± 0.1 | 0.6 ± 0.1 | 0.7 ± 0.1 |
| Scaling Trunk, Week 16 (n=23,67,39,101) | 0.4 ± 0.1 | 0.9 ± 0.1 | 0.6 ± 0.1 | 0.7 ± 0.1 |
| Erythema Lower limbs, Baseline (n=27,75,42,120) | 0.7 ± 0.2 | 2.1 ± 0.1 | 1.1 ± 0.2 | 1.9 ± 0.1 |
| Erythema Lower limbs, Week 4 (n=27,74,42,119) | 0.7 ± 0.2 | 1.6 ± 0.1 | 1.0 ± 0.2 | 1.3 ± 0.1 |
| Erythema Lower limbs, Week 8 (n=26,72,41,118) | 0.8 ± 0.2 | 1.3 ± 0.1 | 0.9 ± 0.2 | 1.0 ± 0.1 |
| Erythema Lower limbs, Week 16 (n=23,67,39,101) | 1.0 ± 0.2 | 1.3 ± 0.1 | 0.9 ± 0.2 | 0.9 ± 0.1 |
| Induration Lower limbs, Baseline (n=27,75,42,120) | 0.6 ± 0.1 | 1.9 ± 0.1 | 1.0 ± 0.2 | 1.7 ± 0.1 |
| Induration Lower limbs, Week 4 (n=27,74,42,119) | 0.7 ± 0.2 | 1.5 ± 0.1 | 0.9 ± 0.2 | 1.0 ± 0.1 |
| Induration Lower limbs, Week 8 (n=26,72,41,118) | 0.7 ± 0.2 | 1.3 ± 0.1 | 0.9 ± 0.2 | 0.9 ± 0.1 |
| Induration Lower limbs, Week 16 (n=23,67,39,101) | 0.9 ± 0.2 | 1.1 ± 0.1 | 0.9 ± 0.2 | 0.8 ± 0.1 |
| Scaling Lower limbs, Baseline (n=27,75,42,120) | 0.6 ± 0.2 | 1.8 ± 0.1 | 1.0 ± 0.2 | 1.8 ± 0.1 |
| Scaling Lower limbs, Week 4 (n=27,74,42,119) | 0.7 ± 0.2 | 1.5 ± 0.1 | 0.9 ± 0.2 | 1.1 ± 0.1 |
| Scaling Lower limbs, Week 8 (n=26,72,41,118) | 0.7 ± 0.2 | 1.2 ± 0.1 | 0.8 ± 0.2 | 1.0 ± 0.1 |
| Scaling Lower limbs, Week 16 (n=23,67,39,101) | 1.0 ± 0.2 | 1.1 ± 0.1 | 0.8 ± 0.2 | 0.8 ± 0.1 |
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.
| score on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Erythema Head/Neck, Week 4 (n=326,331) | -0.8 ± 0.1 | -1.2 ± 0.1 |
| Erythema Head/Neck, Week 8 (n=322,323) | -1.1 ± 0.1 | -1.5 ± 0.1 |
| Erythema Head/Neck, Week 16 (n=311,307) | -1.2 ± 0.1 | -1.6 ± 0.1 |
| Erythema Head/Neck, Week 24 (n=277,279) | -1.2 ± 0.1 | -1.6 ± 0.1 |
| Induration Head/Neck, Week 4 (n=326,331) | -0.8 ± 0.0 | -1.1 ± 0.1 |
| Induration Head/Neck, Week 8 (n=322,323) | -1.1 ± 0.1 | -1.4 ± 0.1 |
| Induration Head/Neck, Week 16 (n=311,307) | -1.2 ± 0.1 | -1.4 ± 0.1 |
| Induration Head/Neck, Week 24 (n=277,279) | -1.1 ± 0.1 | -1.4 ± 0.1 |
| Scaling Head/Neck, Week 4 (n=326,331) | -0.9 ± 0.1 | -1.1 ± 0.1 |
| Scaling Head/Neck, Week 8 (n=322,323) | -1.2 ± 0.1 | -1.5 ± 0.1 |
| Scaling Head/Neck, Week 16 (n=311,307) | -1.3 ± 0.1 | -1.5 ± 0.1 |
| Scaling Head/Neck, Week 24 (n=277,279) | -1.2 ± 0.1 | -1.5 ± 0.1 |
| Erythema Upper limbs, Week 4 (n=326,331) | -0.9 ± 0.0 | -1.2 ± 0.0 |
| Erythema Upper limbs, Week 8 (n=322,323) | -1.3 ± 0.1 | -1.5 ± 0.1 |
| Erythema Upper limbs, Week 16 (n=311,307) | -1.4 ± 0.1 | -1.7 ± 0.1 |
| Erythema Upper limbs, Week 24 (n=277,279) | -1.5 ± 0.1 | -1.8 ± 0.1 |
| Induration Upper limbs, Week 4 (n=326,331) | -0.8 ± 0.0 | -1.2 ± 0.1 |
| Induration Upper limbs, Week 8 (n=322,323) | -1.1 ± 0.1 | -1.5 ± 0.1 |
| Induration Upper limbs, Week 16 (n=311,307 | -1.2 ± 0.1 | -1.6 ± 0.1 |
| Induration Upper limbs, Week 24 (n=277,279) | -1.2 ± 0.1 | -1.6 ± 0.1 |
| Scaling Upper limbs, Week 4 (n=326,331) | -0.7 ± 0.0 | -1.1 ± 0.1 |
| Scaling Upper limbs, Week 8 (n=322,323) | -1.1 ± 0.1 | -1.5 ± 0.1 |
| Scaling Upper limbs, Week 16 (n=311,307) | -1.2 ± 0.1 | -1.6 ± 0.1 |
| Scaling Upper limbs, Week 24 (n=277,279) | -1.3 ± 0.1 | -1.6 ± 0.1 |
| Erythema Trunk, Week 4 (n=326,331) | -0.9 ± 0.0 | -1.3 ± 0.1 |
| Erythema Trunk, Week 8 (n=322,323) | -1.3 ± 0.1 | -1.7 ± 0.1 |
| Erythema Trunk, Week 16 (n=311,307) | -1.5 ± 0.1 | -1.9 ± 0.1 |
| Erythema Trunk, Week 24 (n=277,279) | -1.5 ± 0.1 | -2.0 ± 0.1 |
| Induration Trunk, Week 4 (n=326,331) | -0.8 ± 0.0 | -1.2 ± 0.1 |
| Induration Trunk, Week 8 (n=322,323) | -1.2 ± 0.1 | -1.7 ± 0.1 |
| Induration Trunk, Week 16 (n=311,307) | -1.4 ± 0.1 | -1.8 ± 0.1 |
| Induration Trunk, Week 24 (n=277,279) | -1.4 ± 0.1 | -1.9 ± 0.1 |
| Scaling Trunk, Week 4 (n=326,331) | -0.8 ± 0.1 | -1.1 ± 0.1 |
| Scaling Trunk, Week 8 (n=322,323) | -1.2 ± 0.1 | -1.6 ± 0.1 |
| Scaling Trunk, Week 16 (n=311,307) | -1.4 ± 0.1 | -1.8 ± 0.1 |
| Scaling Trunk, Week 24 (n=277,279) | -1.4 ± 0.1 | -1.8 ± 0.1 |
| Erythema Lower limbs, Week 4 (n=326,331) | -0.9 ± 0.0 | -1.2 ± 0.0 |
| Erythema Lower limbs, Week 8 (n=322,323) | -1.3 ± 0.1 | -1.7 ± 0.1 |
| Erythema Lower limbs, Week 16 (n=311,307) | -1.6 ± 0.1 | -2.0 ± 0.1 |
| Erythema Lower limbs, Week 24 (n=277,279) | -1.7 ± 0.1 | -2.1 ± 0.1 |
| Induration Lower limbs, Week 4 (n=326,331) | -0.8 ± 0.0 | -1.3 ± 0.1 |
| Induration Lower limbs, Week 8 (n=322,323) | -1.2 ± 0.1 | -1.7 ± 0.1 |
| Induration Lower limbs, Week 16 (n=311,307) | -1.5 ± 0.1 | -2.0 ± 0.1 |
| Induration Lower limbs, Week 24 (n=277,279) | -1.6 ± 0.1 | -2.0 ± 0.1 |
| Scaling Lower limbs, Week 4 (n=326,331) | -0.9 ± 0.0 | -1.2 ± 0.1 |
| Scaling Lower limbs, Week 8 (n=322,323) | -1.3 ± 0.1 | -1.8 ± 0.1 |
| Scaling Lower limbs, Week 16 (n=311,307) | -1.6 ± 0.1 | -2.0 ± 0.1 |
| Scaling Lower limbs, Week 24 (n=277,279) | -1.6 ± 0.1 | -2.0 ± 0.1 |
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period B.
| score on a scale | CP-690,550 5 mg BID (Period B) | Placebo for CP-690,550 5 mg BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 (Period B) |
|---|---|---|---|---|
| Erythema Head/Neck, Week 4 (n=30,82,43,128) | 0.1 ± 0.1 | 0.8 ± 0.1 | 0.2 ± 0.1 | 0.8 ± 0.1 |
| Erythema Head/Neck, Week 8 (n=30,70,43,104) | 0.2 ± 0.2 | 0.9 ± 0.1 | 0.1 ± 0.1 | 1.1 ± 0.1 |
| Erythema Head/Neck, Week 12 (n=28,53,42,84) | 0.2 ± 0.1 | 0.8 ± 0.1 | 0.2 ± 0.1 | 0.9 ± 0.1 |
| Erythema Head/Neck, Week 16 (n=28,45,38,70) | 0.1 ± 0.1 | 0.6 ± 0.1 | 0.2 ± 0.1 | 0.8 ± 0.1 |
| Induration Head/Neck, Week 4 (n=30,82,43,128) | 0.1 ± 0.1 | 0.5 ± 0.1 | 0.1 ± 0.1 | 0.7 ± 0.1 |
| Induration Head/Neck, Week 8 (n=30,70,43,104) | 0.1 ± 0.1 | 0.7 ± 0.1 | 0.2 ± 0.1 | 0.9 ± 0.1 |
| Induration Head/Neck, Week 12 (n=28,53,42,84) | 0.1 ± 0.1 | 0.6 ± 0.1 | 0.3 ± 0.1 | 0.8 ± 0.1 |
| Induration Head/Neck, Week 16 (n=28,45,38,70) | 0.1 ± 0.1 | 0.5 ± 0.1 | 0.2 ± 0.1 | 0.7 ± 0.1 |
| Scaling Head/Neck, Week 4 (n=30,82,43,128) | 0.0 ± 0.1 | 0.6 ± 0.1 | 0.2 ± 0.1 | 0.8 ± 0.1 |
| Scaling Head/Neck, Week 8 (n=30,70,43,104) | 0.1 ± 0.1 | 0.8 ± 0.1 | 0.2 ± 0.1 | 1.0 ± 0.1 |
| Scaling Head/Neck, Week 12 (n=28,53,42,84) | 0.1 ± 0.1 | 0.7 ± 0.1 | 0.3 ± 0.1 | 1.0 ± 0.1 |
| Scaling Head/Neck, Week 16 (n=28,45,38,70) | 0.1 ± 0.1 | 0.7 ± 0.1 | 0.3 ± 0.1 | 0.8 ± 0.1 |
| Erythema Upper limbs, Week 4 (n=30,82,43,128) | 0.1 ± 0.1 | 0.7 ± 0.1 | 0.1 ± 0.1 | 0.7 ± 0.1 |
| Erythema Upper limbs, Week 8 (n=30,70,43,104) | 0.3 ± 0.1 | 0.9 ± 0.1 | 0.2 ± 0.1 | 0.9 ± 0.1 |
| Erythema Upper limbs, Week 12 (n=28,53,42,84) | 0.4 ± 0.2 | 0.9 ± 0.1 | 0.2 ± 0.1 | 0.9 ± 0.1 |
| Erythema Upper limbs, Week 16 (n=28,45,38,70) | 0.4 ± 0.1 | 0.8 ± 0.1 | 0.4 ± 0.1 | 0.9 ± 0.1 |
| Induration Upper limbs, Week 4 (n=30,82,43,128) | 0.1 ± 0.1 | 0.6 ± 0.1 | 0.1 ± 0.1 | 0.6 ± 0.1 |
| Induration Upper limbs, Week 8 (n=30,70,43,104) | 0.2 ± 0.1 | 0.9 ± 0.1 | 0.2 ± 0.1 | 0.9 ± 0.1 |
| Induration Upper limbs, Week 12 (n=28,53,42,84) | 0.4 ± 0.2 | 0.9 ± 0.1 | 0.4 ± 0.1 | 0.9 ± 0.1 |
| Induration Upper limbs, Week 16 (n=28,45,38,70) | 0.4 ± 0.2 | 0.9 ± 0.1 | 0.5 ± 0.1 | 0.9 ± 0.1 |
| Scaling Upper limbs, Week 4 (n=30,82,43,128) | 0.1 ± 0.1 | 0.7 ± 0.1 | 0.1 ± 0.1 | 0.7 ± 0.1 |
| Scaling Upper limbs, Week 8 (n=30,70,43,104) | 0.1 ± 0.1 | 0.9 ± 0.1 | 0.1 ± 0.1 | 0.9 ± 0.1 |
| Scaling Upper limbs, Week 12 (n=28,53,42,84) | 0.3 ± 0.1 | 0.9 ± 0.1 | 0.3 ± 0.1 | 1.0 ± 0.1 |
| Scaling Upper limbs, Week 16 (n=28,45,38,70) | 0.3 ± 0.2 | 0.9 ± 0.1 | 0.6 ± 0.1 | 1.1 ± 0.1 |
| Erythema Trunk, Week 4 (n=30,82,43,128) | 0.2 ± 0.1 | 0.7 ± 0.1 | 0.0 ± 0.1 | 0.7 ± 0.1 |
| Erythema Trunk, Week 8 (n=30,70,43,104) | 0.4 ± 0.1 | 1.0 ± 0.1 | 0.1 ± 0.1 | 1.0 ± 0.1 |
| Erythema Trunk, Week 12 (n=28,53,42,84) | 0.1 ± 0.1 | 1.2 ± 0.2 | 0.2 ± 0.1 | 0.8 ± 0.1 |
| Erythema Trunk, Week 16 (n=28,45,38,70) | 0.3 ± 0.2 | 1.0 ± 0.2 | 0.2 ± 0.1 | 0.8 ± 0.1 |
| Induration Trunk, Week 4 (n=30,82,43,128) | -0.0 ± 0.1 | 0.6 ± 0.1 | 0.0 ± 0.1 | 0.5 ± 0.1 |
| Induration Trunk, Week 8 (n=30,70,43,104) | 0.1 ± 0.1 | 0.9 ± 0.1 | 0.2 ± 0.1 | 0.8 ± 0.1 |
| Induration Trunk, Week 12 (n=28,53,42,84) | 0.1 ± 0.1 | 1.0 ± 0.1 | 0.3 ± 0.1 | 0.7 ± 0.1 |
| Induration Trunk, Week 16 (n=28,45,38,70) | 0.2 ± 0.1 | 1.0 ± 0.2 | 0.3 ± 0.1 | 0.8 ± 0.1 |
| Scaling Trunk, Week 4 (n=30,82,43,128) | 0.1 ± 0.1 | 0.6 ± 0.1 | -0.0 ± 0.1 | 0.5 ± 0.1 |
| Scaling Trunk, Week 8 (n=30,70,43,104) | 0.2 ± 0.1 | 0.9 ± 0.1 | 0.2 ± 0.1 | 0.9 ± 0.1 |
| Scaling Trunk, Week 12 (n=28,53,42,84) | 0.1 ± 0.1 | 0.9 ± 0.1 | 0.2 ± 0.1 | 0.6 ± 0.1 |
| Scaling Trunk, Week 16 (n=28,45,38,70) | 0.4 ± 0.2 | 0.9 ± 0.2 | 0.3 ± 0.2 | 0.8 ± 0.1 |
| Erythema Lower limbs, Week 4 (n=30,82,43,128) | 0.1 ± 0.1 | 0.7 ± 0.1 | 0.0 ± 0.1 | 0.8 ± 0.1 |
| Erythema Lower limbs, Week 8 (n=30,70,43,104) | 0.3 ± 0.2 | 1.0 ± 0.1 | -0.0 ± 0.1 | 1.1 ± 0.1 |
| Erythema Lower limbs, Week 12 (n=28,53,42,84) | 0.3 ± 0.2 | 1.0 ± 0.1 | 0.1 ± 0.2 | 1.0 ± 0.1 |
| Erythema Lower limbs, Week 16 (n=28,45,38,70) | 0.3 ± 0.2 | 1.1 ± 0.2 | 0.3 ± 0.2 | 0.9 ± 0.1 |
| Induration Lower limbs, Week 4 (n=30,82,43,128) | 0.1 ± 0.1 | 0.5 ± 0.1 | 0.0 ± 0.1 | 0.7 ± 0.1 |
| Induration Lower limbs, Week 8 (n=30,70,43,104) | 0.1 ± 0.2 | 0.9 ± 0.1 | 0.0 ± 0.1 | 1.0 ± 0.1 |
| Induration Lower limbs, Week 12 (n=28,53,42,84) | 0.1 ± 0.2 | 0.9 ± 0.1 | 0.2 ± 0.1 | 0.9 ± 0.1 |
| Induration Lower limbs, Week 16 (n=28,45,38,70) | 0.1 ± 0.1 | 0.9 ± 0.1 | 0.4 ± 0.2 | 0.9 ± 0.1 |
| Scaling Lower limbs, Week 4 (n=30,82,43,128) | 0.1 ± 0.1 | 0.6 ± 0.1 | -0.0 ± 0.1 | 0.6 ± 0.1 |
| Scaling Lower limbs, Week 8 (n=30,70,43,104) | 0.3 ± 0.2 | 0.9 ± 0.1 | -0.0 ± 0.1 | 0.9 ± 0.1 |
| Scaling Lower limbs, Week 12 (n=28,53,42,84) | 0.2 ± 0.2 | 0.9 ± 0.1 | 0.0 ± 0.1 | 0.9 ± 0.1 |
| Scaling Lower limbs, Week 16 (n=28,45,38,70) | 0.2 ± 0.2 | 1.0 ± 0.1 | 0.3 ± 0.2 | 1.0 ± 0.1 |
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). PASI score can vary in increments of 0.1; higher scores represent greater severity of psoriasis. Baseline defined as last observation up to first dosing date in Period C.
| score on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Erythema Head/Neck, Week 4 (n=27,74,42,119) | -0.1 ± 0.1 | -0.4 ± 0.1 | 0.1 ± 0.1 | -0.9 ± 0.1 |
| Erythema Head/Neck, Week 8 (n=26,72,41,118) | 0.1 ± 0.1 | -0.7 ± 0.1 | -0.0 ± 0.1 | -0.9 ± 0.1 |
| Erythema Head/Neck, Week 16 (n=23,67,39,101) | -0.1 ± 0.1 | -0.4 ± 0.1 | -0.1 ± 0.1 | -0.9 ± 0.1 |
| Induration Head/Neck, Week 4 (n=27,74,42,119) | -0.2 ± 0.1 | -0.4 ± 0.1 | 0.0 ± 0.1 | -0.8 ± 0.1 |
| Induration Head/Neck, Week 8 (n=26,72,41,118) | -0.0 ± 0.2 | -0.5 ± 0.1 | -0.0 ± 0.1 | -0.8 ± 0.1 |
| Induration Head/Neck, Week 16 (n=23,67,39,101) | -0.1 ± 0.1 | -0.6 ± 0.1 | -0.2 ± 0.1 | -0.9 ± 0.1 |
| Scaling Head/Neck, Week 4 (n=27,74,42,119) | -0.1 ± 0.1 | -0.4 ± 0.1 | 0.0 ± 0.1 | -0.9 ± 0.1 |
| Scaling Head/Neck, Week 8 (n=26,72,41,118) | 0.1 ± 0.1 | -0.5 ± 0.1 | -0.0 ± 0.1 | -0.9 ± 0.1 |
| Scaling Head/Neck, Week 16 (n=23,67,39,101) | -0.1 ± 0.1 | -0.5 ± 0.1 | -0.2 ± 0.1 | -1.0 ± 0.1 |
| Erythema Upper limbs, Week 4 (n=27,74,42,119) | -0.0 ± 0.1 | -0.4 ± 0.1 | -0.0 ± 0.1 | -0.6 ± 0.1 |
| Erythema Upper limbs, Week 8 (n=26,72,41,118) | -0.1 ± 0.1 | -0.7 ± 0.1 | -0.1 ± 0.1 | -0.8 ± 0.1 |
| Erythema Upper limbs, Week 16 (n=23,67,39,101) | 0.0 ± 0.2 | -0.6 ± 0.1 | -0.2 ± 0.2 | -0.8 ± 0.1 |
| Induration Upper limbs, Week 4 (n=27,74,42,119) | -0.0 ± 0.1 | -0.5 ± 0.1 | -0.0 ± 0.1 | -0.6 ± 0.1 |
| Induration Upper limbs, Week 8 (n=26,72,41,118) | -0.0 ± 0.1 | -0.7 ± 0.1 | -0.1 ± 0.1 | -0.8 ± 0.1 |
| Induration Upper limbs, Week 16 (n=23,67,39,101) | -0.0 ± 0.2 | -0.6 ± 0.1 | -0.1 ± 0.2 | -0.8 ± 0.1 |
| Scaling Upper limbs, Week 4 (n=27,74,42,119) | 0.0 ± 0.1 | -0.3 ± 0.1 | -0.2 ± 0.1 | -0.7 ± 0.1 |
| Scaling Upper limbs, Week 8 (n=26,72,41,118) | -0.0 ± 0.2 | -0.6 ± 0.1 | -0.1 ± 0.1 | -0.8 ± 0.1 |
| Scaling Upper limbs, Week 16 (n=23,67,39,101) | 0.0 ± 0.2 | -0.5 ± 0.1 | -0.2 ± 0.2 | -0.8 ± 0.1 |
| Erythema Trunk, Week 4 (n=27,74,42,119) | -0.1 ± 0.1 | -0.5 ± 0.1 | -0.1 ± 0.1 | -0.8 ± 0.1 |
| Erythema Trunk, Week 8 (n=26,72,41,118) | -0.1 ± 02 | -0.7 ± 01 | 0.0 ± 0.2 | -1.0 ± 0.1 |
| Erythema Trunk, Week 16 (n=23,67,39,101) | -0.2 ± 0.2 | -0.8 ± 0.1 | -0.1 ± 0.2 | -1.0 ± 0.1 |
| Induration Trunk, Week 4 (n=27,74,42,119) | -0.1 ± 0.1 | -0.5 ± 0.1 | -0.1 ± 0.1 | -0.7 ± 0.1 |
| Induration Trunk, Week 8 (n=26,72,41,118) | -0.1 ± 0.1 | -0.7 ± 0.1 | -0.2 ± 0.1 | -0.8 ± 0.1 |
| Induration Trunk, Week 16 (n=23,67,39,101) | -0.2 ± 0.2 | -0.8 ± 0.1 | -0.2 ± 0.2 | -0.8 ± 0.1 |
| Scaling Trunk, Week 4 (n=27,74,42,119) | -0.2 ± 0.2 | -0.4 ± 0.1 | -0.1 ± 0.1 | -0.6 ± 0.1 |
| Scaling Trunk, Week 8 (n=26,72,41,118) | 0.0 ± 0.1 | -0.6 ± 0.1 | -0.1 ± 0.1 | -0.8 ± 0.1 |
| Scaling Trunk, Week 16 (n=23,67,39,101) | -0.3 ± 0.2 | -0.7 ± 0.1 | -0.1 ± 0.1 | -0.8 ± 0.1 |
| Erythema Lower limbs, Week 4 (n=27,74,42,119) | 0.0 ± 0.1 | -0.5 ± 0.1 | -0.1 ± 0.1 | -0.7 ± 0.1 |
| Erythema Lower limbs, Week 8 (n=26,72,41,118) | 0.1 ± 0.1 | -0.7 ± 0.1 | -0.2 ± 0.1 | -0.9 ± 0.1 |
| Erythema Lower limbs, Week 16 (n=23,67,39,101) | 0.2 ± 0.2 | -0.7 ± 0.1 | -0.2 ± 0.2 | -1.0 ± 0.1 |
| Induration Lower limbs, Week 4 (n=27,74,42,119) | 0.2 ± 0.1 | -0.4 ± 0.1 | -0.1 ± 0.1 | -0.7 ± 0.1 |
| Induration Lower limbs, Week 8 (n=26,72,41,118) | 0.1 ± 0.2 | -0.6 ± 0.1 | -0.1 ± 0.1 | -0.8 ± 0.1 |
| Induration Lower limbs, Week 16 (n=23,67,39,101) | 0.3 ± 0.2 | -0.7 ± 0.1 | -0.1 ± 0.2 | -0.9 ± 0.1 |
| Scaling Lower limbs, Week 4 (n=27,74,42,119) | 0.1 ± 0.1 | -0.3 ± 0.1 | -0.1 ± 0.1 | -0.7 ± 0.1 |
| Scaling Lower limbs, Week 8 (n=26,72,41,118) | 0.1 ± 0.2 | -0.6 ± 0.1 | -0.1 ± 0.1 | -0.8 ± 0.1 |
| Scaling Lower limbs, Week 16 (n=23,67,39,101) | 0.3 ± 0.2 | -0.6 ± 0.1 | -0.2 ± 0.2 | -0.9 ± 0.1 |
PASI quantifies the severity of psoriasis based on both lesion severity and the percent of BSA) affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of the body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.
| percentage of participants | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 | 28.70 (23.83 to 33.57) | 54.63 (49.30 to 59.96) |
| Week 8 | 55.29 (49.93 to 60.64) | 75.52 (70.92 to 80.13) |
| Week 16 | 65.26 (60.13 to 70.39) | 79.40 (75.07 to 83.73) |
| Week 24 | 59.52 (54.23 to 64.80) | 73.13 (68.39 to 77.88) |
PASI quantifies the severity of psoriasis based on both lesion severity and the percent of BSA) affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of the body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.
| percentage of participants | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 | 1.21 (0.03 to 2.39) | 6.27 (3.67 to 8.86) |
| Week 8 | 8.76 (5.72 to 11.81) | 24.78 (20.15 to 29.40) |
| Week 16 | 18.73 (14.53 to 22.93) | 36.72 (31.55 to 41.88) |
| Week 24 | 20.24 (15.91 to 24.57) | 37.31 (32.13 to 42.49) |
PASI quantifies the severity of psoriasis based on both lesion severity and the percent of BSA) affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of the body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.
| percentage of participants | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 | 0.91 (0.0 to 1.93) | 2.09 (0.56 to 3.62) |
| Week 8 | 2.72 (0.97 to 4.47) | 7.46 (4.65 to 10.28) |
| Week 16 | 7.25 (4.46 to 10.04) | 15.82 (11.91 to 19.73) |
| Week 24 | 8.16 (5.21 to 11.11) | 17.31 (13.26 to 21.37) |
PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline | 96.30 (89.17 to 100.00) | 42.67 (31.47 to 53.86) | 92.86 (85.07 to 100.00) | 49.17 (40.22 to 58.11) |
| Week 4 | 100.00 (100.00 to 100.00) | 69.33 (58.90 to 79.77) | 92.86 (85.07 to 100.00) | 84.17 (77.64 to 90.70) |
| Week 8 | 92.59 (82.71 to 100.00) | 81.33 (72.52 to 90.15) | 95.24 (88.80 to 100.00) | 89.17 (83.61 to 94.73) |
| Week 16 | 85.19 (71.79 to 98.58) | 82.67 (74.10 to 91.23) | 85.71 (75.13 to 96.30) | 79.17 (71.90 to 86.43) |
PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline | 48.15 (29.30 to 66.99) | 12.00 (4.65 to 19.35) | 45.24 (30.19 to 60.29) | 15.83 (9.30 to 22.36) |
| Week 4 | 48.15 (29.30 to 66.99) | 17.33 (8.77 to 25.90) | 47.62 (32.51 to 62.72) | 35.00 (26.47 to 43.53) |
| Week 8 | 48.15 (29.3 to 66.99) | 21.33 (12.06 to 30.60) | 47.62 (32.51 to 62.72) | 42.50 (33.66 to 51.34) |
| Week 16 | 33.33 (15.55 to 51.11) | 21.33 (12.06 to 30.60) | 45.24 (30.19 to 60.29) | 44.17 (35.28 to 53.05) |
PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline | 18.52 (3.87 to 33.17) | 5.33 (0.25 to 10.42) | 23.81 (10.93 to 36.69) | 5.00 (1.10 to 8.90) |
| Week 4 | 18.52 (3.87 to 33.17) | 9.33 (2.75 to 15.92) | 21.43 (9.02 to 33.84) | 15.00 (8.61 to 21.39) |
| Week 8 | 18.52 (3.87 to 33.17) | 13.33 (5.64 to 21.03) | 21.43 (9.02 to 33.84) | 19.17 (12.12 to 26.21) |
| Week 16 | 14.81 (1.42 to 28.21) | 10.67 (3.68 to 17.65) | 26.19 (12.89 to 39.49) | 20.83 (13.57 to 28.10) |
PASI quantifies the severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by the investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head and neck, upper limbs, trunk, and lower limbs), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis.
| percentage of participants | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 (n=326,331) | 0.92 (0.00 to 1.96) | 0.60 (0.00 to 1.44) |
| Week 8 (n=322,323) | 0.62 (0.00 to 1.48) | 0.62 (0.00 to 1.47) |
| Week 16 (n=311,307) | 0.96 (0.00 to 2.05) | 0.98 (0.00 to 2.08) |
| Week 24 (n=277,279) | 1.08 (0.00 to 2.30) | 0.36 (0.00 to 1.06) |
| Overall (n=329,333) | 2.13 (0.57 to 3.69) | 2.10 (0.56 to 3.64) |
PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
| percentage of participants | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Week 4 (n=30,82,43,128) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Week 8 (n=30,70,43,104) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Week 12 (n=28,53,42,84) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (-3.51 to 1.13) | 1.19 |
| Week 16 (n=28,45,38,70) | 0.00 | 0.00 | 0.00 | 0.00 |
| Overall (n=31,82,45,132) | 0.00 | 0.00 | 0.00 | 0.76 |
PASI quantifies severity of psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite score by investigator of degree of erythema, induration, and scaling (scored separately) for each of 4 body regions (head/neck, upper limbs, trunk, lower limbs), with adjustment for percent of BSA involved for each body region and for proportion of body region to the whole body. PASI score can vary in increments of 0.1 and range from 0.0-72.0; higher scores representing greater severity of psoriasis. Baseline-A defined as last observation up to first dosing date in Period A.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Week 4 (n=27,74,42,119) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Week 8 (n=26,72,41,118) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Week 16 (n=23,67,39,101) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 2.56 (0.00 to 7.52) | 0.00 (0.00 to 0.00) |
| Overall (n=27,75,42,120) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 2.38 (0.00 to 6.99) | 0.00 (0.00 to 0.00) |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| score on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Baseline (n=331,335) | 6.7 ± 0.1 | 6.9 ± 0.1 |
| Week 4 (n=326,331) | 3.2 ± 0.1 | 2.2 ± 0.1 |
| Week 8 (n=322,321) | 2.8 ± 0.1 | 1.6 ± 0.1 |
| Week 16 (n=310,307) | 2.9 ± 0.2 | 1.7 ± 0.1 |
| Week 24 (n=274,278) | 2.9 ± 0.2 | 1.6 ± 0.1 |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| score on a scale | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Baseline (n=31,82,45,133) | 1.5 ± 0.4 | 1.2 ± 0.2 | 0.6 ± 0.2 | 0.8 ± 0.1 |
| Week 4 (n=30,82,43,127) | 1.7 ± 0.4 | 3.6 ± 0.3 | 0.7 ± 0.2 | 4.1 ± 0.3 |
| Week 8 (n=30,69,43,104) | 1.5 ± 0.4 | 4.0 ± 0.4 | 1.2 ± 0.3 | 4.1 ± 0.3 |
| Week 12 (n=29,53,41,84) | 1.9 ± 0.4 | 4.0 ± 0.4 | 1.3 ± 0.3 | 3.8 ± 0.3 |
| Week 16 (n=28,45,38,70) | 2.2 ± 0.5 | 3.7 ± 0.4 | 1.6 ± 0.4 | 4.0 ± 0.4 |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| score on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline (n=27,75,42,120) | 2.3 ± 0.5 | 4.9 ± 0.3 | 1.7 ± 0.4 | 5.2 ± 0.3 |
| Week 4 (n=27,74,42,119) | 2.6 ± 0.5 | 2.6 ± 0.2 | 1.7 ± 0.4 | 2.1 ± 0.2 |
| Week 8 (n=26,72,41,118) | 2.4 ± 0.5 | 2.3 ± 0.2 | 1.5 ± 0.3 | 1.8 ± 0.2 |
| Week 16 (n=23,67,39,100) | 2.3 ± 0.5 | 2.2 ± 0.3 | 1.4 ± 0.4 | 1.6 ± 0.2 |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. Baseline-A defined as the last observation up to first dosing date in Period A.
| score on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 (n=326,331) | -3.6 ± 0.1 | -4.6 ± 0.2 |
| Week 8 (n=322,321) | -3.9 ± 0.2 | -5.3 ± 0.2 |
| Week 16 (n=310,307) | -3.8 ± 0.2 | -5.2 ± 0.2 |
| Week 24 (n=274,278) | -3.7 ± 0.2 | -5.3 ± 0.2 |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. Baseline-B defined as the last observation up to first dosing date in Period B.
| score on a scale | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Week 4 (n=30,82,43,127) | 0.2 ± 0.3 | 2.4 ± 0.3 | 0.1 ± 0.2 | 3.3 ± 0.3 |
| Week 8 (n=30,69,43,104) | -0.0 ± 0.3 | 2.9 ± 0.3 | 0.6 ± 0.2 | 3.4 ± 0.3 |
| Week 12 (n=29,53,41,84) | 0.3 ± 0.2 | 2.8 ± 0.3 | 0.7 ± 0.2 | 3.2 ± 0.3 |
| Week 16 (n=28,45,38,70) | 0.6 ± 0.3 | 2.7 ± 0.4 | 0.9 ± 0.3 | 3.6 ± 0.4 |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. Baseline-C defined as the last observation up to first dosing date in Period C.
| score on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Week 4 (n=27,74,42,119) | 0.3 ± 0.4 | -2.3 ± 0.3 | 0.0 ± 0.2 | -3.1 ± 0.3 |
| Week 8 (n=26,72,41,118) | 0.1 ± 0.4 | -2.6 ± 0.3 | -0.2 ± 0.2 | -3.4 ± 0.3 |
| Week 16 (n=23,67,39,100) | 0.4 ± 0.4 | -2.6 ± 0.4 | -0.3 ± 0.3 | -3.6 ± 0.3 |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| percentage of participants | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 | 12.92 (9.28 to 16.57) | 25.69 (20.95 to 30.42) |
| Week 8 | 16.92 (12.85 to 21.00) | 41.28 (35.95 to 46.62) |
| Week 16 | 20.00 (15.65 to 24.35) | 37.92 (32.66 to 43.18) |
| Week 24 | 19.38 (15.09 to 23.68) | 37.31 (32.07 to 42.55) |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Week 4 | 0.00 (0.00 to 0.00) | 11.27 (3.91 to 18.62) | 7.41 (0.00 to 17.29) | 23.08 (14.98 to 31.17) |
| Week 8 | 5.56 (0.00 to 16.14) | 18.31 (9.31 to 27.31) | 18.52 (3.87 to 33.17) | 38.46 (29.11 to 47.81) |
| Week 16 | 11.11 (0.00 to 25.63) | 15.49 (7.08 to 23.91) | 25.93 (9.40 to 42.46) | 28.85 (20.14 to 37.55) |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| percentage of participants | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 | 27.62 (22.68 to 32.56) | 46.03 (40.53 to 51.54) |
| Week 8 | 34.29 (29.04 to 39.53) | 60.00 (54.59 to 65.41) |
| Week 16 | 34.92 (29.66 to 40.19) | 60.00 (54.59 to 65.41) |
| Week 24 | 31.11 (26.00 to 36.22) | 55.24 (49.75 to 60.73) |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Week 4 | 14.29 (0.00 to 32.62) | 22.58 (12.17 to 32.99) | 14.29 (0.00 to 32.62) | 41.05 (31.16 to 50.94) |
| Week 8 | 21.43 (0.00 to 42.92) | 33.87 (22.09 to 45.65) | 21.43 (0.00 to 42.92) | 55.79 (45.80 to 65.78) |
| Week 16 | 21.43 (0.00 to 42.92) | 41.94 (29.65 to 54.22) | 35.71 (10.61 to 60.81) | 50.53 (40.47 to 60.58) |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| percentage of participants | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 | 81.59 (77.31 to 85.87) | 88.89 (85.42 to 92.36) |
| Week 8 | 80.32 (75.93 to 84.71) | 87.94 (84.34 to 91.53) |
| Week 16 | 73.97 (69.12 to 78.81) | 84.76 (80.79 to 88.73) |
| Week 24 | 65.71 (60.47 to 70.96) | 74.92 (70.13 to 79.71) |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Week 4 | 28.57 (4.91 to 52.24) | 61.29 (49.17 to 73.41) | 14.29 (0.00 to 32.62) | 80.00 (71.96 to 88.04) |
| Week 8 | 28.57 (4.91 to 52.24) | 64.52 (52.61 to 76.43) | 28.57 (4.91 to 52.24) | 78.95 (70.75 to 87.15) |
| Week 16 | 21.43 (0.00 to 42.92) | 62.90 (50.88 to 74.93) | 28.57 (4.91 to 52.24) | 69.47 (60.21 to 78.73) |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| percentage of participants | CP-690,550 5 mg (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 | 27.8 (23.2 to 33.2) | 47.2 (41.8 to 52.9) |
| Week 8 | 41.2 (36.0 to 46.9) | 67.8 (62.5 to 72.9) |
| Week 16 | 52.4 (46.8 to 58.2) | 78.6 (73.7 to 83.1) |
| Week 24 | 72.4 (55.1 to 87.3) | 83.4 (77.9 to 88.2) |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| weeks | CP-690,550 5 mg (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Median Time to ISI Score of ≤1 During the Initial CP-690,550 Treatment (Period A) | 16.4 (16.1 to 24.6) | 8.0 (5.1 to 8.1) |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Week 4 | 14.3 (3.8 to 46.1) | 22.8 (14.2 to 35.5) | 14.3 (3.8 to 46.1) | 41.3 (32.1 to 51.9) |
| Week 8 | 28.6 (11.8 to 59.4) | 37.9 (27.0 to 51.4) | 21.4 (7.5 to 52.8) | 59.8 (50.0 to 69.7) |
| Week 16 | 40.5 (18.3 to 73.5) | 79.1 (46.8 to 98.0) | 49.5 (21.8 to 85.0) | 90.3 (69.9 to 98.9) |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| weeks | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Median Time to ISI Score of ≤1 During the CP-690,550 Re-Treatment (Period C) | NA (NA to NA) | 16.1 (10.1 to NA) | NA (NA to NA) | 8.3 (6.0 to 12.4) |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| percentage of participants | CP-690,550 5 mg (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 | 82.2 (77.8 to 86.2) | 90.3 (86.7 to 93.3) |
| Week 8 | 89.5 (85.8 to 92.6) | 96.5 (94.0 to 98.2) |
| Week 16 | 93.6 (90.5 to 96.0) | 97.8 (95.5 to 99.1) |
| Week 24 | 96.2 (92.5 to 98.4) | 97.8 (95.5 to 99.1) |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| weeks | CP-690,550 5 mg (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Median Time to ISI Reduction (2-point Decrease in ISI Score) During the Initial CP-690,550 Treatment (Period A) | 4.1 (NA to NA) | 4.1 (NA to NA) |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Week 4 | 28.6 (11.8 to 59.4) | 61.8 (49.9 to 73.8) | 14.3 (3.8 to 46.1) | 80.0 (71.5 to 87.3) |
| Week 8 | 35.7 (16.7 to 65.7) | 75.1 (63.8 to 85.1) | 28.6 (11.8 to 59.4) | 86.7 (78.9 to 92.6) |
| Week 16 | 57.1 (25.6 to 91.1) | 100.0 (NA to NA) | 36.5 (17.0 to 66.9) | 91.0 (83.6 to 95.9) |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends.
| weeks | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Median Time to ISI Reduction (2-point Decrease in ISI Score) During the CP-690,550 Re-Treatment (Period C) | 16.6 (4.4 to NA) | 4.9 (4.3 to 7.1) | NA (NA to NA) | 4.3 (4.1 to 4.4) |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
| score on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Baseline (n=330,333) | 12.6 ± 0.4 | 12.6 ± 0.4 |
| Week 4 (n=326,330) | 6.8 ± 0.3 | 4.8 ± 0.3 |
| Week 8 (n=321,319) | 5.4 ± 0.3 | 3.4 ± 0.3 |
| Week 16 (n=310,303) | 4.7 ± 0.3 | 2.9 ± 0.3 |
| Week 24 (n=273,277) | 5.1 ± 0.4 | 2.6 ± 0.3 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
| score on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline (n=27,75,42,120) | 3.6 ± 1.0 | 7.0 ± 0.8 | 2.2 ± 0.5 | 8.8 ± 0.7 |
| Week 4 (n=27,74,42,119) | 3.4 ± 1.0 | 4.3 ± 0.5 | 2.2 ± 0.5 | 3.9 ± 0.4 |
| Week 8 (n=26,71,41,118) | 3.9 ± 1.3 | 3.1 ± 0.4 | 2.2 ± 0.5 | 2.7 ± 0.4 |
| Week 16 (n=22,66,39,101) | 3.0 ± 1.0 | 3.4 ± 0.5 | 2.1 ± 0.7 | 2.4 ± 0.4 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
| score on a scale | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Baseline (n=31,82,45,133) | 2.6 ± 0.7 | 1.8 ± 0.3 | 1.2 ± 0.3 | 1.2 ± 0.2 |
| Week 4 (n=30,82,43,127) | 3.4 ± 0.9 | 4.7 ± 0.5 | 1.3 ± 0.4 | 5.9 ± 0.6 |
| Week 8 (n=30,68,43,104) | 3.1 ± 0.9 | 5.9 ± 0.8 | 1.6 ± 0.5 | 6.4 ± 0.7 |
| Week 12 (n=28,52,41,83) | 3.3 ± 1.1 | 4.7 ± 0.6 | 1.9 ± 0.4 | 5.3 ± 0.7 |
| Week 16 (n=28,44,38,68) | 3.5 ± 1.0 | 5.0 ± 0.7 | 2.0 ± 0.4 | 6.2 ± 0.8 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-A defined as the last observation up to first dosing date in Period A.
| scores on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 (n=325,328) | -5.8 ± 0.3 | -7.6 ± 0.3 |
| Week 8 (n=320,317) | -7.1 ± 0.3 | -9.1 ± 0.4 |
| Week 16 (n=309,301) | -7.6 ± 0.4 | -9.4 ± 0.4 |
| Week 24 (n=272,275) | -7.1 ± 0.4 | -9.7 ± 0.4 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-B defined as the last observation up to first dosing date in Period B.
| scores on a scale | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Week 4 (n=30,82,43,127) | 0.8 ± 0.7 | 3.0 ± 0.5 | 0.1 ± 0.3 | 4.6 ± 0.5 |
| Week 8 (n=30,68,43,104) | 0.5 ± 0.3 | 4.1 ± 0.7 | 0.3 ± 0.5 | 5.4 ± 0.6 |
| Week 12 (n=28,52,41,83) | 0.9 ± 0.5 | 3.4 ± 0.5 | 0.6 ± 0.4 | 4.5 ± 0.7 |
| Week 16 (n=28,44,38,68) | 1.1 ± 0.5 | 3.6 ± 0.6 | 0.5 ± 0.3 | 5.4 ± 0.8 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-C defined as the last observation up to first dosing date in Period C.
| scores on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Week 4 (n=27,74,42,119) | -0.2 ± 0.2 | -2.9 ± 0.5 | 0.0 ± 0.4 | -4.9 ± 0.6 |
| Week 8 (n=26,71,41,118) | 0.2 ± 0.4 | -3.4 ± 0.5 | -0.0 ± 0.5 | -5.9 ± 0.6 |
| Week 16 (n=22,66,39,101) | 0.5 ± 0.8 | -3.3 ± 0.8 | -0.0 ± 0.7 | -6.3 ± 0.7 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).
| score on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Daily Activities, Baseline (n=330,333) | 2.7 ± 0.10 | 2.7 ± 0.10 |
| Daily Activities, Week 4 (n=326,330) | 1.5 ± 0.09 | 1.1 ± 0.07 |
| Daily Activities, Week 8 (n=321,320) | 1.2 ± 0.08 | 0.8 ± 0.07 |
| Daily Activities, Week 16 (n=310,303) | 1.0 ± 0.08 | 0.6 ± 0.07 |
| Daily Activities, Week 24 (n=273,277) | 1.1 ± 0.09 | 0.6 ± 0.07 |
| Personal Relationships, Baseline (n=331,332) | 1.7 ± 0.10 | 1.7 ± 0.10 |
| Personal Relationships, Week 4 (n=326,330) | 1.0 ± 0.08 | 0.6 ± 0.07 |
| Personal Relationships, Week 8 (n=321,318) | 0.7 ± 0.06 | 0.4 ± 0.06 |
| Personal Relationships, Week 16 (n=310,302) | 0.6 ± 0.06 | 0.3 ± 0.06 |
| Personal Relationships, Week 24 (n=271,276) | 0.6 ± 0.07 | 0.3 ± 0.05 |
| Symptoms and Feelings, Baseline (n=331,333) | 3.9 ± 0.09 | 3.9 ± 0.08 |
| Symptoms and Feelings, Week 4 (n=326,330) | 2.1 ± 0.07 | 1.6 ± 0.07 |
| Symptoms and Feelings, Week 8 (n=321,319) | 1.8 ± 0.08 | 1.2 ± 0.07 |
| Symptoms and Feelings, Week 16 (n=310,303) | 1.7 ± 0.08 | 1.1 ± 0.08 |
| Symptoms and Feelings, Week 24 (n=273,277) | 1.7 ± 0.09 | 1.0 ± 0.08 |
| Leisure, Baseline (n=331,333) | 2.1 ± 0.11 | 2.2 ± 0.11 |
| Leisure, Week 4 (n=326,330) | 1.1 ± 0.09 | 0.8 ± 0.07 |
| Leisure, Week 8 (n=321,320) | 0.9 ± 0.08 | 0.5 ± 0.06 |
| Leisure, Week 16 (n=310,303) | 0.7 ± 0.07 | 0.4 ± 0.06 |
| Leisure, Week 24 (n=272,277) | 0.8 ± 0.08 | 0.4 ± 0.05 |
| Work and School, Baseline (n=330,333) | 0.9 ± 0.06 | 0.9 ± 0.06 |
| Work and School, Week 4 (n=326,330) | 0.5 ± 0.05 | 0.3 ± 0.04 |
| Work and School, Week 8 (n=321,319) | 0.3 ± 0.04 | 0.2 ± 0.03 |
| Work and School, Week 16 (n=309,303) | 0.3 ± 0.04 | 0.2 ± 0.03 |
| Work and School, Week 24 (n=273,277) | 0.4 ± 0.04 | 0.1 ± 0.03 |
| Treatment, Baseline (n=331,332) | 1.1 ± 0.06 | 1.2 ± 0.06 |
| Treatment, Week 4 (n=326,330) | 0.6 ± 0.04 | 0.5 ± 0.04 |
| Treatment, Week 8 (n=321,320) | 0.5 ± 0.04 | 0.4 ± 0.03 |
| Treatment, Week 16 (n=310,303) | 0.5 ± 0.04 | 0.3 ± 0.04 |
| Treatment, Week 24 (n=272,277) | 0.6 ± 0.05 | 0.2 ± 0.03 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).
| score on a scale | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Daily Activities, Baseline (n=31,82,45,133) | 0.5 ± 0.18 | 0.3 ± 0.07 | 0.2 ± 0.07 | 0.3 ± 0.07 |
| Daily Activities, Week 4 (n=30,82,43,127) | 0.8 ± 0.30 | 0.8 ± 0.14 | 0.3 ± 0.09 | 1.2 ± 0.14 |
| Daily Activities, Week 8 (n=30,68,43,104) | 0.6 ± 0.25 | 1.1 ± 0.19 | 0.4 ± 0.13 | 1.2 ± 0.17 |
| Daily Activities, Week 12 (n=28,52,41,83) | 0.6 ± 0.23 | 0.9 ± 0.15 | 0.3 ± 0.10 | 1.1 ± 0.17 |
| Daily Activities, Week 16 (n=28,44,38,68) | 0.6 ± 0.22 | 1.2 ± 0.21 | 0.4 ± 0.12 | 1.3 ± 0.21 |
| Personal Relationships, Baseline (n=31,82,45,133) | 0.3 ± 0.13 | 0.2 ± 0.06 | 0.2 ± 0.08 | 0.1 ± 0.04 |
| Personal Relationships, Week 4 (n=30,82,43,126) | 0.4 ± 0.19 | 0.6 ± 0.11 | 0.1 ± 0.05 | 0.6 ± 0.10 |
| Personal Relationships, Week 8 (n=30,68,43,103) | 0.4 ± 0.22 | 0.8 ± 0.17 | 0.1 ± 0.07 | 0.9 ± 0.14 |
| Personal Relationships, Week 12 (n=28,52,41,83) | 0.4 ± 0.23 | 0.6 ± 0.15 | 0.1 ± 0.05 | 0.7 ± 0.13 |
| Personal Relationships, Week 16 (n=28,44,38,68) | 0.4 ± 0.23 | 0.5 ± 0.16 | 0.2 ± 0.07 | 0.8 ± 0.17 |
| Symptoms and Feelings, Baseline (n=31,82,45,133) | 1.1 ± 0.25 | 0.8 ± 0.10 | 0.5 ± 0.10 | 0.6 ± 0.08 |
| Symptoms and Feelings, Week 4 (n=30,82,43,127) | 1.3 ± 0.30 | 2.0 ± 0.19 | 0.5 ± 0.13 | 2.2 ± 0.16 |
| Symptoms and Feelings, Week 8 (n=30,68,43,104) | 1.1 ± 0.24 | 2.2 ± 0.19 | 0.7 ± 0.16 | 2.3 ± 0.18 |
| Symptoms and Feelings, Week 12 (n=28,52,41,83) | 1.1 ± 0.28 | 2.1 ± 0.19 | 1.0 ± 0.19 | 2.0 ± 0.18 |
| Symptoms and Feelings, Week 16 (n=28,44,38,68) | 1.4 ± 0.31 | 1.9 ± 0.19 | 1.0 ± 0.16 | 2.2 ± 0.21 |
| Leisure, Baseline (n=31,82,45,133) | 0.3 ± 0.12 | 0.2 ± 0.07 | 0.2 ± 0.08 | 0.2 ± 0.05 |
| Leisure, Week 4 (n=30,82,42,127) | 0.5 ± 0.23 | 0.6 ± 0.11 | 0.1 ± 0.08 | 0.9 ± 0.13 |
| Leisure, Week 8 (n=30,68,43,104) | 0.5 ± 0.15 | 0.8 ± 0.18 | 0.2 ± 0.11 | 0.9 ± 0.15 |
| Leisure, Week 12 (n=28,52,41,83) | 0.5 ± 0.18 | 0.5 ± 0.14 | 0.2 ± 0.07 | 0.7 ± 0.14 |
| Leisure, Week 16 (n=28,44,37,68) | 0.5 ± 0.17 | 0.5 ± 0.15 | 0.1 ± 0.07 | 0.9 ± 0.17 |
| Work and School, Baseline (n=31,82,45,133) | 0.1 ± 0.04 | 0.1 ± 0.05 | 0.0 ± 0.02 | 0.1 ± 0.02 |
| Work and School, Week 4 (n=30,82,43,127) | 0.1 ± 0.06 | 0.3 ± 0.07 | 0.0 ± 0.02 | 0.5 ± 0.09 |
| Work and School, Week 8 (n=30,68,43,104) | 0.2 ± 0.08 | 0.3 ± 0.09 | 0.0 ± 0.03 | 0.5 ± 0.09 |
| Work and School, Week 12 (n=28,52,41,83) | 0.2 ± 0.13 | 0.2 ± 0.06 | 0.1 ± 0.05 | 0.4 ± 0.09 |
| Work and School, Week 16 (n=28,44,38,68) | 0.3 ± 0.13 | 0.3 ± 0.08 | 0.0 ± 0.03 | 0.4 ± 0.10 |
| Treatment, Baseline (n=31,82,45,133) | 0.3 ± 0.10 | 0.1 ± 0.04 | 0.2 ± 0.05 | 0.1 ± 0.03 |
| Treatment, Week 4 (n=30,82,43,127) | 0.3 ± 0.10 | 0.4 ± 0.07 | 0.2 ± 0.06 | 0.5 ± 0.08 |
| Treatment, Week 8 (n=30,68,43,104) | 0.3 ± 0.10 | 0.5 ± 0.09 | 0.1 ± 0.05 | 0.6 ± 0.09 |
| Treatment, Week 12 (n=28,52,41,83) | 0.4 ± 0.14 | 0.4 ± 0.09 | 0.2 ± 0.09 | 0.5 ± 0.08 |
| Treatment, Week 16 (n=28,44,38,68) | 0.3 ± 0.12 | 0.6 ± 0.11 | 0.2 ± 0.07 | 0.6 ± 0.11 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3).
| score on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Daily Activities, Baseline (n=27,75,42,120) | 0.7 ± 0.23 | 1.5 ± 0.19 | 0.4 ± 0.12 | 1.8 ± 0.17 |
| Daily Activities, Week 4 (n=27,74,42,119) | 0.6 ± 0.24 | 0.9 ± 0.14 | 0.5 ± 0.14 | 0.8 ± 0.11 |
| Daily Activities, Week 8 (n=26,71,41,118) | 0.9 ± 0.33 | 0.7 ± 0.12 | 0.4 ± 0.14 | 0.5 ± 0.09 |
| Daily Activities, Week 16 (n=22,65,39,101) | 0.7 ± 0.27 | 0.8 ± 0.14 | 0.4 ± 0.15 | 0.5 ± 0.10 |
| Personal Relationships, Baseline (n=27,75,42,120) | 0.4 ± 0.23 | 0.9 ± 0.16 | 0.1 ± 0.06 | 1.2 ± 0.15 |
| Personal Relationships, Week 4 (n=27,74,42,119) | 0.4 ± 0.24 | 0.5 ± 0.10 | 0.2 ± 0.09 | 0.5 ± 0.10 |
| Personal Relationships, Week 8 (n=26,71,41,118) | 0.4 ± 0.25 | 0.2 ± 0.07 | 0.3 ± 0.12 | 0.3 ± 0.09 |
| Personal Relationships, Week 16 (n=22,66,39,101) | 0.2 ± 0.16 | 0.3 ± 0.09 | 0.1 ± 0.11 | 0.2 ± 0.06 |
| Symptoms and Feelings, Baseline (n=27,75,42,120) | 1.4 ± 0.32 | 2.6 ± 0.19 | 1.1 ± 0.20 | 2.9 ± 0.18 |
| Symptoms and Feelings, Week 4 (n=27,74,42,119) | 1.4 ± 0.27 | 1.6 ± 0.15 | 1.0 ± 0.20 | 1.4 ± 0.11 |
| Symptoms and Feelings, Week 8 (n=26,71,41,118) | 1.5 ± 0.36 | 1.5 ± 0.14 | 1.0 ± 0.18 | 1.0 ± 0.12 |
| Symptoms and Feelings, Week 16 (n=22,66,39,101) | 1.2 ± 0.27 | 1.5 ± 0.15 | 0.9 ± 0.22 | 1.0 ± 0.12 |
| Leisure, Baseline (n=27,75,42,120) | 0.5 ± 0.18 | 0.9 ± 0.18 | 0.1 ± 0.06 | 1.4 ± 0.16 |
| Leisure, Week 4 (n=27,74,41,119) | 0.4 ± 0.17 | 0.6 ± 0.13 | 0.2 ± 0.09 | 0.6 ± 0.10 |
| Leisure, Week 8 (n=26,71,41,118) | 0.5 ± 0.22 | 0.4 ± 0.08 | 0.3 ± 0.10 | 0.4 ± 0.09 |
| Leisure, Week 16 (n=22,66,39,101) | 0.4 ± 0.24 | 0.4 ± 0.10 | 0.3 ± 0.13 | 0.4 ± 0.09 |
| Work and School, Baseline (n=27,75,42,120) | 0.3 ± 0.14 | 0.5 ± 0.09 | 0.1 ± 0.04 | 0.6 ± 0.09 |
| Work and School, Week 4 (n=27,74,42,119) | 0.2 ± 0.12 | 0.2 ± 0.08 | 0.1 ± 0.04 | 0.2 ± 0.05 |
| Work and School, Week 8 (n=26,71,41,118) | 0.2 ± 0.14 | 0.1 ± 0.04 | 0.0 ± 0.03 | 0.2 ± 0.05 |
| Work and School, Week 16 (n =22,66,39,101) | 0.2 ± 0.14 | 0.2 ± 0.05 | 0.2 ± 0.09 | 0.1 ± 0.05 |
| Treatment, Baseline (n=27,75,42,120) | 0.3 ± 0.13 | 0.7 ± 0.10 | 0.3 ± 0.09 | 0.9 ± 0.09 |
| Treatment, Week 4 (n=27,74,42,119) | 0.3 ± 0.10 | 0.4 ± 0.08 | 0.2 ± 0.09 | 0.4 ± 0.05 |
| Treatment, Week 8 (n=26,71,41,118) | 0.3 ± 0.14 | 0.3 ± 0.06 | 0.1 ± 0.05 | 0.3 ± 0.05 |
| Treatment, Week 16 (n=22,66,39,101) | 0.2 ± 0.09 | 0.2 ± 0.06 | 0.2 ± 0.08 | 0.3 ± 0.05 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-A defined as the last observation up to first dosing date in Period A.
| scores on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Daily Activities, Week 4 (n=325,328) | -1.2 ± 0.09 | -1.6 ± 0.09 |
| Daily Activities, Week 8 (n=320,318) | -1.5 ± 0.10 | -1.9 ± 0.10 |
| Daily Activities, Week 16 (n=309,301) | -1.7 ± 0.10 | -2.0 ± 0.10 |
| Daily Activities, Week 24 (n=272,275) | -1.6 ± 0.11 | -2.0 ± 0.11 |
| Personal Relationships, Week 4 (n=326,327) | -0.8 ± 0.08 | -1.0 ± 0.09 |
| Personal Relationships, Week 8 (n=321,316) | -1.0 ± 0.08 | -1.3 ± 0.09 |
| Personal Relationships, Week 16 (n=310,300) | -1.1 ± 0.09 | -1.3 ± 0.10 |
| Personal Relationships, Week 24 (n=271,274) | -1.0 ± 0.10 | -1.3 ± 0.10 |
| Symptoms and Feelings, Week 4 (n=326,328) | -1.9 ± 0.08 | -2.3 ± 0.08 |
| Symptoms and Feelings, Week 8 (n=321,317) | -2.2 ± 0.09 | -2.7 ± 0.09 |
| Symptoms and Feelings, Week 18 (n=310,301) | -2.2 ± 0.09 | -2.8 ± 0.10 |
| Symptoms and Feelings, Week 24 (n=273,275) | -2.1 ± 0.11 | -2.9 ± 0.10 |
| Leisure, Week 4 (n=326,328) | -1.0 ± 0.10 | -1.4 ± 0.10 |
| Leisure, Week 16 (n=310,301) | -1.4 ± 0.11 | -1.7 ± 0.11 |
| Leisure, Week 8 (n=321,318) | -1.2 ± 0.10 | -1.7 ± 0.10 |
| Leisure, Week 24 (n=272,275) | -1.3 ± 0.12 | -1.8 ± 0.12 |
| Work and School, Week 4 (n=325,328) | -0.4 ± 0.05 | -0.6 ± 0.06 |
| Work and School, Week 8 (n=320,317) | -0.6 ± 0.05 | -0.7 ± 0.06 |
| Work and School, Week 16 (n=308,301) | -0.6 ± 0.06 | -0.7 ± 0.06 |
| Work and School, Week 24 (n=272,275) | -0.5 ± 0.06 | -0.7 ± 0.06 |
| Treatment, Week 4 (n=326,327) | -0.5 ± 0.06 | -0.7 ± 0.05 |
| Treatment, Week 8 (n=321,317) | -0.6 ± 0.06 | -0.8 ± 0.06 |
| Treatment, Week 16 (n=310,300) | -0.6 ± 0.06 | -0.9 ± 0.06 |
| Treatment, Week 24 (n=272,274) | -0.5 ± 0.06 | -1.0 ± 0.06 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-B defined as the last observation up to first dosing date in Period B.
| scores on a scale | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Daily Activities, Week 4 (n=30,82,43,127) | 0.3 ± 0.22 | 0.5 ± 0.14 | 0.1 ± 0.08 | 0.9 ± 0.13 |
| Daily Activities, Week 8 (n=30,68,43,104) | 0.1 ± 0.09 | 0.8 ± 0.17 | 0.2 ± 0.13 | 1.0 ± 0.17 |
| Daily Activities, Week 12 (n=28,52,41,83) | 0.2 ± 0.13 | 0.7 ± 0.14 | 0.1 ± 0.11 | 0.9 ± 0.17 |
| Daily Activities, Week 16 (n=28,44,38,68) | 0.2 ± 0.12 | 0.9 ± 0.19 | 0.2 ± 0.10 | 1.1 ± 0.22 |
| Personal Relationships, Week 4 (n=30,82,43,126) | 0.0 ± 0.11 | 0.4 ± 0.10 | -0.1 ± 0.08 | 0.5 ± 0.09 |
| Personal Relationships, Week 8 (n=30,68,43,103) | 0.1 ± 0.15 | 0.6 ± 0.15 | -0.1 ± 0.09 | 0.8 ± 0.13 |
| Personal Relationships, Week 12 (n=28,52,41,83) | 0.1 ± 0.14 | 0.4 ± 0.14 | -0.1 ± 0.09 | 0.6 ± 0.13 |
| Personal Relationships, Week 16 (n=28,44,38,68) | 0.1 ± 0.15 | 0.3 ± 0.15 | -0.1 ± 0.10 | 0.8 ± 0.17 |
| Symptoms and Feelings, Week 4 (n=30,82,43,127) | 0.2 ± 0.25 | 1.3 ± 0.17 | 0.1 ± 0.13 | 1.7 ± 0.14 |
| Symptoms and Feelings, Week 8 (n=30,68,43,104) | 0.0 ± 0.13 | 1.5 ± 0.17 | 0.2 ± 0.17 | 1.8 ± 0.16 |
| Symptoms and Feelings, Week 12 (n=28,52,41,83) | 0.1 ± 0.19 | 1.4 ± 0.18 | 0.5 ± 0.19 | 1.6 ± 0.18 |
| Symptoms and Feelings, Week 16 (n=28,44,38,68) | 0.4 ± 0.21 | 1.3 ± 0.22 | 0.5 ± 0.14 | 1.8 ± 0.21 |
| Leisure, Week 4 (n=30,82,42,127) | 0.2 ± 0.22 | 0.3 ± 0.11 | -0.1 ± 0.09 | 0.7 ± 0.12 |
| Leisure, Week 8 (n=30,68,43,104) | 0.1 ± 0.10 | 0.5 ± 0.16 | 0.0 ± 0.10 | 0.8 ± 0.15 |
| Leisure, Week 12 (n=28,52,41,83) | 0.2 ± 0.12 | 0.4 ± 0.11 | 0.0 ± 0.09 | 0.6 ± 0.15 |
| Leisure, Week 16 (n=28,44,37,68) | 0.2 ± 0.12 | 0.4 ± 0.12 | -0.1 ± 0.08 | 0.8 ± 0.18 |
| Work and School, Week 4 (n=30,82,43,127) | 0.0 ± 0.6 | 0.2 ± 0.07 | 0.0 ± 0.00 | 0.5 ± 0.08 |
| Work and School, Week 8 (n=30,68,43,104) | 0.1 ± 0.06 | 0.2 ± 0.09 | 0.0 ± 0.02 | 0.4 ± 0.08 |
| Work and School, Week 12 (n=28,52,41,83) | 0.1 ± 0.08 | 0.1 ± 0.07 | 0.1 ± 0.04 | 0.3 ± 0.09 |
| Work and School, Week 16 (n=28,44,38,68) | 0.2 ± 0.10 | 0.2 ± 0.09 | 0.0 ± 0.00 | 0.4 ± 0.10 |
| Treatment, Week 4 (n=30,82,43,127) | 0.0 ± 0.07 | 0.2 ± 0.06 | 0.1 ± 0.06 | 0.4 ± 0.07 |
| Treatment, Week 8 (n=30,68,43,104) | 0.0 ± 0.06 | 0.4 ± 0.09 | 0.0 ± 0.06 | 0.6 ± 0.08 |
| Treatment, Week 12 (n=28,52,41,83) | 0.1 ± 0.11 | 0.3 ± 0.7 | 0.0 ± 0.09 | 0.4 ± 0.09 |
| Treatment, Week 16 (n=28,44,38,68) | 0.0 ± 0.10 | 0.5 ± 0.11 | 0.1 ± 0.05 | 0.5 ± 0.10 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much); higher scores indicate poor quality of life. The DLQI can be analyzed under 6 subscales by combining questions and is categorized as follows: symptoms and feelings (maximum score=6); daily activities (maximum score=6); leisure (maximum score=6); work and school (maximum score=3); personal relationships (maximum score=6); and treatment (maximum score=3). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-C defined as the last observation up to first dosing date in Period C.
| scores on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Daily Activities, Week 4 (n=27,74,42,119) | 0.0 ± 0.06 | -0.7 ± 0.12 | 0.1 ± 0.11 | -1.0 ± 0.13 |
| Daily Activities, Week 8 (n=26,71,41,118) | 0.2 ± 0.15 | -0.7 ± 0.13 | 0.0 ± 0.14 | -1.3 ± 0.15 |
| Daily Activities, Week 16 (n=22,65,39,101) | 0.4 ± 0.23 | -0.7 ± 0.20 | -0.1 ± 0.18 | -1.3 ± 0.18 |
| Personal Relationships, Week 4 (n=27,74,42,119) | 0.0 ± 0.05 | -0.4 ± 0.11 | 0.1 ± 0.08 | -0.7 ± 0.13 |
| Personal Relationships, Week 8 (n=26,71,41,118) | 0.0 ± 0.07 | -0.6 ± 0.13 | 0.1 ± 0.13 | -0.8 ± 0.14 |
| Personal Relationships, Week 16 (n=22,66,39,101) | 0.0 ± 0.11 | -0.6 ± 0.14 | 0.1 ± 0.12 | -0.9 ± 0.15 |
| Symptoms and Feelings, Week 4 (n=27,74,42,119) | 0.0 ± 0.14 | -1.0 ± 0.13 | -0.1 ± 0.13 | -1.5 ± 0.15 |
| Symptoms and Feelings, Week 8 (n=26,71,41,118) | 0.0 ± 0.14 | -1.1 ± 0.17 | -0.1 ± 0.18 | -1.8 ± 0.18 |
| Symptoms and Feelings, Week 16 (n=22,66,39,101) | 0.0 ± 0.20 | -1.0 ± 0.20 | -0.2 ± 0.21 | -1.9 ± 0.19 |
| Leisure, Week 4 (n=27,74,41,119) | -0.1 ± 0.08 | -0.3 ± 0.14 | 0.1 ± 0.06 | -0.8 ± 0.13 |
| Leisure, Week 8 (n=26,71,41,118) | 0.0 ± 0.13 | -0.4 ± 0.13 | 0.1 ± 0.10 | -1.0 ± 0.15 |
| Leisure, Week 16 (n=22,66,39,101) | 0.0 ± 0.28 | -0.4 ± 0.17 | 0.2 ± 0.12 | -1.1 ± 0.18 |
| Work and School, Week 4 (n=27,74,42,119) | 0.0 ± 0.06 | -0.2 ± 0.07 | 0.0 ± 0.03 | -0.4 ± 0.08 |
| Work and School, Week 8 (n=26,71,41,118) | 0.0 ± 0.7 | -0.3 ± 0.09 | 0.0 ± 0.06 | -0.4 ± 0.09 |
| Work and School, Week 16 (n=22,66,39,101) | 0.0 ± 0.07 | -0.3 ± 0.10 | 0.1 ± 0.09 | -0.5 ± 0.09 |
| Treatment, Week 4 (n=27,74,42,119) | 0.0 ± 0.08 | -0.2 ± 0.08 | 0.0 ± 0.07 | -0.6 ± 0.07 |
| Treatment, Week 8 (n=26,71,41,118) | 0.0 ± 0.07 | -0.3 ± 0.08 | -0.2 ± 0.09 | -0.07 ± 0.09 |
| Treatment, Week 16 (n=22,66,39,101) | 0.0 ± 0.08 | -0.3 ± 0.09 | -0.1 ± 0.11 | -0.7 ± 0.10 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
| percentage of participants | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 | 59.86 (54.16 to 65.56) | 75.44 (70.41 to 80.48) |
| Week 8 | 70.42 (65.11 to 75.73) | 80.78 (76.18 to 85.39) |
| Week 16 | 70.77 (65.49 to 76.06) | 79.00 (74.24 to 83.77) |
| Week 24 | 59.86 (54.16 to 65.56) | 72.95 (67.76 to 78.15) |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
| percentage of participants | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Week 4 | 0.00 | 16.67 | 33.33 | 0.00 |
| Week 8 | 0.00 | 0.00 | 0.00 | 11.11 |
| Week 12 | 11.11 | 0.00 | 66.67 | 11.11 |
| Week 16 | 0.00 | 8.33 | 33.33 | 11.11 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline. Baseline-C defined as the last observation up to first dosing date in Period C.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Week 4 | 0.00 (0.00 to 0.00) | 47.50 (32.02 to 62.98) | 0.00 (0.00 to 0.00) | 65.79 (55.12 to 76.46) |
| Week 8 | 12.50 (0.00 to 35.42) | 55.00 (39.58 to 70.42) | 25.00 (0.00 to 55.01) | 77.63 (68.26 to 87.00) |
| Week 16 | 12.50 (0.00 to 35.42) | 47.50 (32.02 to 62.98) | 12.50 (0.00 to 35.42) | 64.47 (53.71 to 75.23) |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
| percentage of participants | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 | 13.44 (9.70 to 17.17) | 26.88 (22.02 to 31.73) |
| Week 8 | 25.94 (21.14 to 30.74) | 41.88 (36.47 to 47.28) |
| Week 16 | 30.94 (25.87 to 36.00) | 53.13 (47.66 to 58.59) |
| Week 24 | 30.63 (25.57 to 35.68) | 50.00 (44.52 to 55.48) |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
| percentage of participants | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Baseline | 0.00 | 0.00 | 0.00 | 0.00 |
| Week 4 | 7.69 | 4.00 | 41.67 | 12.90 |
| Week 8 | 7.69 | 0.00 | 33.33 | 9.68 |
| Week 12 | 7.69 | 0.00 | 8.33 | 9.68 |
| Week 16 | 7.69 | 0.00 | 16.67 | 9.68 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| Week 4 | 16.67 (0.00 to 37.75) | 24.59 (13.78 to 35.40) | 37.50 (13.78 to 61.22) | 24.73 (15.96 to 33.50) |
| Week 8 | 16.67 (0.00 to 37.75) | 26.23 (15.19 to 37.27) | 31.25 (8.54 to 53.96) | 40.86 (30.87 to 50.85) |
| Week 16 | 16.67 (0.00 to 37.75) | 29.51 (18.06 to 40.95) | 37.50 (13.78 to 61.22) | 40.86 (30.87 to 50.85) |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Severity is measured using the following categories of scores: 0-1=no effect on patients' lives; 2-5=small effect; 6-10=moderate effect; 11-20=very large effect; 21-30=extremely large effect.
| percentage of participants | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Baseline, No effect (0-1) (n=330,333) | 3.0 ± 3.0 | 3.9 ± 3.9 |
| Baseline, Small effect (2-5;n=330,333) | 15.2 ± 15.2 | 17.1 ± 17.1 |
| Baseline, Moderate effect (6-10;n=330,333) | 27.0 ± 27.0 | 21.3 ± 21.3 |
| Baseline, Very large effect (11-20;n=330,333) | 39.1 ± 39.1 | 41.7 ± 41.7 |
| Baseline, Extremely large effect (21-30;n=330,333) | 15.8 ± 15.8 | 15.9 ± 15.9 |
| Week 4, No effect (0-1) (n=326,330) | 15.6 ± 15.6 | 29.4 ± 29.4 |
| Week 4, Small effect (2-5;n=326,330) | 35.9 ± 35.9 | 37.3 ± 37.3 |
| Week 4, Moderate effect (6-10;n=326,330) | 25.8 ± 25.8 | 22.1 ± 22.1 |
| Week 4, Very large effect (11-20;n=326,330) | 18.7 ± 18.7 | 9.7 ± 9.7 |
| Week 4, Extremely large effect (21-30;n=326,330) | 4.0 ± 4.0 | 1.5 ± 1.5 |
| Week 8, No effect (0-1) (n=321,319) | 28.0 ± 28.0 | 45.5 ± 45.5 |
| Week 8, Small effect (2-5;n=321,319) | 34.0 ± 34.0 | 34.8 ± 34.8 |
| Week 8, Moderate effect (6-10;n=321,319) | 23.7 ± 23.7 | 12.5 ± 12.5 |
| Week 8, Very large effect (11-20;n=321,319) | 11.8 ± 11.8 | 5.0 ± 5.0 |
| Week 8, Extremely large effect (21-30;n=321,319) | 2.5 ± 2.5 | 2.2 ± 2.2 |
| Week 16, No effect (0-1) (n=310,303) | 34.2 ± 34.2 | 59.4 ± 59.4 |
| Week 16, Small effect (2-5;n=310,303) | 34.5 ± 34.5 | 22.1 ± 22.1 |
| Week 16, Moderate effect (6-10;n=310,303) | 18.4 ± 18.4 | 10.6 ± 10.6 |
| Week 16, Very large effect (11-20;n=310,303) | 11.0 ± 11.0 | 6.3 ± 6.3 |
| Week 16, Extremely large effect (21-30;n=310,303) | 1.9 ± 1.9 | 1.7 ± 1.7 |
| Week 24, No effect (0-1) (n=273,277) | 38.1 ± 38.1 | 61.0 ± 61.0 |
| Week 24, Small effect (2-5;n=273,277) | 27.1 ± 27.1 | 24.9 ± 24.9 |
| Week 24, Moderate effect (6-10;n=273,277) | 19.0 ± 19.0 | 9.0 ± 9.0 |
| Week 24, Very large effect (11-20;n=273,277) | 12.8 ± 12.8 | 3.2 ± .32 |
| Week 24, Extremely large effect (21-30;n=273,277) | 2.9 ± 2.9 | 1.8 ± 1.8 |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
| percentage of participants | CP-690,550 5 mg (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 | 60.1 (54.5 to 65.9) | 76.6 (71.5 to 81.4) |
| Week 8 | 77.4 (72.4 to 82.2) | 88.7 (84.6 to 92.2) |
| Week 16 | 85.7 (81.3 to 89.6) | 94.9 (91.6 to 97.2) |
| Week 24 | 91.9 (83.2 to 97.1) | 96.1 (92.9 to 98.1) |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
| weeks | CP-690,550 5 mg (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During Initial CP-690,550 Treatment (Period A) | 4.4 (4.3 to 4.7) | 4.1 (4.1 to 4.3) |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life. The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Week 4 | 0.0 (0.0 to 0.0) | 47.5 (33.5 to 63.9) | 0.0 (0.0 to 0.0) | 65.8 (55.2 to 76.2) |
| Week 8 | 12.5 (1.9 to 61.3) | 72.5 (58.3 to 85.1) | 25.0 (6.9 to 68.5) | 80.9 (71.3 to 88.9) |
| Week 16 | 12.5 (1.9 to 61.3) | 81.3 (67.3 to 91.9) | 25.0 (6.9 to 68.5) | 88.4 (79.1 to 94.8) |
The DLQI is a general dermatology questionnaire that consists of 10 items that assess health related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The minimally important difference for the DLQI has been estimated as a 2 to 5 point change from baseline.
| weeks | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Median Time to DLQI ≥5-Point Reduction From Baseline-A Response During CP-690,550 Re-Treatment (Period C) | NA (NA to NA) | 8.1 (4.7 to 8.6) | NA (NA to NA) | 4.4 (4.3 to 5.7) |
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and standard deviations (SDs) of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.
| score on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Baseline Physical Health Score (n=330,334) | 48.1 ± 0.5 | 47.8 ± 0.5 |
| Week 24 Physical Health Score (n=273,276) | 50.5 ± 0.5 | 52.9 ± 0.5 |
| Baseline Mental Health Score (n=330,334) | 45.2 ± 0.7 | 46.1 ± 0.6 |
| Week 24 Mental Health Score (n=273,276) | 48.9 ± 0.6 | 51.2 ± 0.6 |
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and SDs of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.
| score on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline Physical Health Score (n=27,75,42,120) | 51.8 ± 1.8 | 49.9 ± 1.1 | 53.8 ± 1.1 | 49.7 ± 0.8 |
| Week 56 Physical Health Score (n=22,65,34,98) | 52.9 ± 1.8 | 52.7 ± 1.0 | 52.9 ± 1.4 | 51.2 ± 0.9 |
| Baseline Mental Health Score (n=27,75,42,120) | 51.7 ± 1.9 | 51.0 ± 1.1 | 50.8 ± 1.9 | 48.3 ± 1.0 |
| Week 56 Mental Health Score (n=22,65,34,98) | 50.8 ± 1.8 | 50.9 ± 1.2 | 52.4 ± 1.5 | 53.7 ± 0.8 |
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and SDs of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.
| scores on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Physical Health Score | 1.9 ± 0.5 | 5.2 ± 0.5 |
| Mental Health Score | 3.2 ± 0.6 | 4.9 ± 0.6 |
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A PCS score and MCS score are based on a normalized sum of the 8 scale scores; PCS/MCS summary concept score = (raw score\*10) plus 50. Linear transformations were performed to transform scores to a mean of 50 and SDs of 10, in the general population. In norm-based scoring, each scale is scored to have same average (50)/SD (10). With this method anytime a scale score is below 50, health status is below average, and each point is one-tenth of a SD. Higher scores indicate a better health related quality of life.
| scores on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Physical Health Score | -0.9 ± 1.2 | 2.7 ± 0.8 | -1.0 ± 0.8 | 1.8 ± 0.9 |
| Mental Health Score | -1.6 ± 1.2 | 0.1 ± 1.0 | 0.5 ± 1.9 | 4.9 ± 1.0 |
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.
| score on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Baseline Physical Functioning (n=331,335) | 48.3 ± 0.6 | 48.0 ± 0.6 |
| Week 24 Physical Functioning (n=273,276) | 50.7 ± 0.6 | 52.7 ± 0.5 |
| Baseline Role Physical (n=331,335) | 47.2 ± 0.6 | 47.6 ± 0.6 |
| Week 24 Role Physical (n=273,276) | 50.2 ± 0.6 | 53.1 ± 0.5 |
| Baseline Bodily Pain (n=331,334) | 44.7 ± 0.6 | 44.2 ± 0.7 |
| Week 24 Bodily Pain (n=273,276) | 50.0 ± 0.6 | 53.2 ± 0.5 |
| Baseline General Health (n=330,335) | 48.1 ± 0.5 | 48.9 ± 0.5 |
| Week 24 General Health (n=273,276) | 49.0 ± 0.6 | 50.3 ± 0.5 |
| Baseline Vitality (n=331,334) | 49.2 ± 0.6 | 49.3 ± 0.5 |
| Week 24 Vitality (n=273,276) | 51.0 ± 0.6 | 54.2 ± 0.5 |
| Baseline Social Functioning (n=331,334) | 44.6 ± 0.7 | 44.6 ± 0.7 |
| Week 24 Social Functioning (n=273,276) | 48.9 ± 0.6 | 51.7 ± 0.5 |
| Baseline Role Emotional (n=331,335) | 45.5 ± 0.7 | 45.8 ± 0.7 |
| Week 24 Role Emotional (n=273,276) | 49.2 ± 0.6 | 51.2 ± 0.5 |
| Baseline Mental Health (n=331,334) | 45.0 ± 0.6 | 46.4 ± 0.6 |
| Week 24 Mental Health (n=273,276) | 48.8 ± 0.6 | 51.0 ± 0.6 |
| Baseline Health Transition Score (n=331,334) | 3.0 ± 0.0 | 3.1 ± 0.0 |
| Week 24 Health Transition Score (n=272, 276) | 2.8 ± 0.0 | 2.8 ± 0.0 |
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life.
| score on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline Physical Functioning (n=27,75,42,120) | 50.7 ± 1.8 | 51.3 ± 1.0 | 52.7 ± 1.3 | 51.1 ± 0.8 |
| Week 56 Physical Functioning (n=22,65,34,98) | 51.7 ± 1.9 | 52.4 ± 1.1 | 52.3 ± 1.6 | 51.3 ± 0.9 |
| Baseline Role Physical (n=27,75,42,120) | 51.2 ± 1.6 | 50.5 ± 1.0 | 53.3 ± 1.1 | 49.1 ± 0.9 |
| Week 56 Role Physical (n=22,65,34,98) | 52.5 ± 1.6 | 51.4 ± 1.2 | 54.2 ± 1.1 | 51.9 ± 0.8 |
| Baseline Bodily Pain (n=27,75,42,120) | 52.8 ± 1.9 | 48.8 ± 1.2 | 54.1 ± 1.5 | 47.1 ± 1.1 |
| Week 56 Bodily Pain (n=22,65,34,98) | 53.9 ± 2.1 | 52.7 ± 1.0 | 53.5 ± 1.8 | 52.7 ± 0.9 |
| Baseline General Health (n=27,75,42,120) | 52.0 ± 1.7 | 49.6 ± 1.1 | 51.9 ± 1.4 | 48.7 ± 0.9 |
| Week 56 General Health (n=22,65,34,98) | 51.5 ± 1.8 | 51.8 ± 1.0 | 51.1 ± 1.4 | 50.7 ± 0.8 |
| Baseline Vitality (n=27,75,42,120) | 53.8 ± 2.2 | 52.2 ± 1.1 | 54.1 ± 1.5 | 51.3 ± 0.9 |
| Week 56 Vitality (n=22,65,34,98) | 52.2 ± 2.2 | 53.2 ± 1.1 | 54.8 ± 1.7 | 54.3 ± 0.9 |
| Baseline Social Functioning (n=27,75,42,120) | 51.2 ± 1.8 | 49.7 ± 1.0 | 51.5 ± 1.4 | 48.1 ± 1.0 |
| Week 56 Social Functioning (n=22,65,34,98) | 52.2 ± 1.6 | 52.4 ± 1.0 | 51.3 ± 1.7 | 53.2 ± 0.6 |
| Baseline Role Emotional (n=27,75,42,120) | 51.1 ± 1.8 | 51.6 ± 0.8 | 50.3 ± 1.7 | 48.0 ± 1.0 |
| Week 56 Role Emotional (n=22,65,34,98) | 50.5 ± 1.8 | 50.0 ± 1.3 | 52.9 ± 1.1 | 53.0 ± 0.6 |
| Baseline Mental Health (n=27,75,42,120) | 51.2 ± 2.0 | 50.2 ± 1.1 | 51.6 ± 1.8 | 48.4 ± 1.0 |
| Week 56 Mental Health (n=22,65,34,98) | 51.1 ± 1.8 | 51.1 ± 1.2 | 52.2 ± 1.5 | 52.7 ± 0.8 |
| Baseline Health Transition (n=27,75,42,120) | 2.9 ± 0.1 | 3.1 ± 0.1 | 2.8 ± 0.1 | 3.0 ± 0.1 |
| Week 56 Health Transition (n=22,65,34,98) | 3.0 ± 0.1 | 2.7 ± 0.1 | 2.8 ± 0.1 | 2.8 ± 0.1 |
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life. Baseline-A defined as the last observation up to first dosing date in Period A.
| scores on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Physical Functioning (n=273,276) | 1.8 ± 0.5 | 4.6 ± 0.5 |
| Role Physical (n=273,276) | 2.6 ± 0.7 | 5.6 ± 0.6 |
| Bodily Pain (n=273,275) | 4.5 ± 0.7 | 9.0 ± 0.7 |
| General Health (n=273,276) | 0.7 ± 0.5 | 1.7 ± 0.4 |
| Vitality (n=273,275) | 1.3 ± 0.5 | 4.8 ± 0.5 |
| Social Functioning (n=273,275) | 3.7 ± 0.7 | 6.6 ± 0.7 |
| Role Emotional (n=273,276) | 3.2 ± 0.8 | 5.6 ± 0.7 |
| Mental Health (n=273,275) | 3.4 ± 0.6 | 4.4 ± 0.6 |
| Health Transition (n=272,275) | -0.2 ± 0.1 | -0.2 ± 0.0 |
The SF-36 is a general health status questionnaire that assesses 8 domains of functional health and well being: Physical Functioning, Role Limitations due to Physical Health Problems, Bodily Pain, Social Functioning, Mental Health, Role Limitations due to Emotional Problems, Vitality, and General Health Perceptions. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Higher scores indicate a better health related quality of life. Baseline-C defined as the last observation up to first dosing date in Period C.
| scores on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Physical Functioning | -0.4 ± 0.7 | 1.2 ± 0.7 | -0.5 ± 0.7 | 0.7 ± 0.9 |
| Role Physical | -0.7 ± 0.9 | 1.2 ± 1.1 | 0.2 ± 0.8 | 2.7 ± 0.9 |
| Bodily Pain | -1.6 ± 1.6 | 3.8 ± 1.1 | -1.1 ± 1.4 | 6.0 ± 1.2 |
| General Health | -0.7 ± 0.9 | 1.9 ± 0.8 | -1.1 ± 0.9 | 1.6 ± 0.8 |
| Vitality | -3.5 ± 1.3 | 1.1 ± 0.9 | 0.2 ± 1.6 | 3.1 ± 1.0 |
| Social Functioning | -1.5 ± 0.7 | 2.6 ± 1.1 | -1.3 ± 1.9 | 4.7 ± 1.0 |
| Role Emotional | -1.4 ± 1.0 | -1.3 ± 1.2 | 1.9 ± 1.6 | 4.6 ± 1.0 |
| Mental Health | -0.1 ± 1.5 | 1.1 ± 0.9 | -0.5 ± 1.5 | 4.1 ± 1.0 |
| Health Transition Score | -0.0 ± 0.1 | -0.3 ± 0.1 | 0.1 ± 0.1 | -0.2 ± 0.1 |
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe
| percentage of participants | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Baseline, Clear (n=330,335) | 0.0 | 0.0 |
| Baseline, Almost clear (n=330,335) | 0.0 | 0.3 |
| Baseline, Mild (n=330,335) | 3.6 | 1.2 |
| Baseline, Moderate (n=330,335) | 30.3 | 34.6 |
| Baseline Severe (n=330,335) | 66.1 | 63.9 |
| Week 4, Clear (n=325,331) | 0.3 | 1.2 |
| Week 4, Almost Clear (n=325,331) | 11.7 | 20.2 |
| Week 4, Mild (n=325,331) | 24.9 | 30.5 |
| Week 4, Moderate (n=325,331) | 40.6 | 37.8 |
| Week 4, Severe (n=325,331) | 22.5 | 10.3 |
| Week 8, Clear (n=320,321) | 1.9 | 5.9 |
| Week 8, Almost Clear (n=320,321) | 21.3 | 41.4 |
| Week 8, Mild (n=320,321) | 31.9 | 25.2 |
| Week 8, Moderate (n=320,321) | 30.0 | 22.4 |
| Week 8, Severe (n=320,321) | 15.0 | 5.0 |
| Week 16, Clear (n=310,303) | 5.5 | 16.8 |
| Week 16, Almost Clear (n=310,303) | 27.1 | 43.6 |
| Week 16, Mild (n=310,303) | 30.6 | 20.8 |
| Week 16, Moderate (n=310,303) | 27.7 | 11.9 |
| Week 16, Severe (n=310,303) | 9.0 | 6.9 |
| Week 24, Clear (n=273,277) | 8.1 | 20.9 |
| Week 24, Almost Clear (n=273,277) | 27.8 | 41.5 |
| Week 24, Mild (n=273,277) | 23.8 | 20.2 |
| Week 24, Moderate (n=273,277) | 30.0 | 13.4 |
| Week 24, Severe (n=273,277) | 10.3 | 4.0 |
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe.
| percentage of participants | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Baseline, Clear (n=31,82,45,133) | 16.1 | 19.5 | 24.4 | 35.3 |
| Baseline, Almost Clear (n=31,82,45,133) | 45.2 | 61.0 | 62.2 | 46.6 |
| Baseline, Mild (n=31,82,45,133) | 25.8 | 12.2 | 11.1 | 15.0 |
| Baseline, Moderate (n=31,82,45,133) | 12.9 | 7.3 | 2.2 | 3.0 |
| Baseline, Severe (n=31,82,45,133) | 0.0 | 0.0 | 0.0 | 0.0 |
| Week 4, Clear (n=30,82,43,126) | 23.3 | 8.5 | 23.3 | 11.1 |
| Week 4, Almost Clear (n=30,82,43,126) | 43.3 | 34.1 | 58.1 | 33.3 |
| Week 4, Mild (n=30,82,43,126) | 23.3 | 30.5 | 11.6 | 17.5 |
| Week 4, Moderate (n=30,82,43,126) | 6.7 | 15.9 | 7.0 | 27.0 |
| Week 4, Severe (n=30,82,43,126) | 3.3 | 11.0 | 0.0 | 11.1 |
| Week 8, Clear (n=30,68,43,104) | 23.3 | 7.4 | 20.9 | 5.8 |
| Week 8, Almost Clear (n=30,68,43,104) | 30.0 | 27.9 | 48.8 | 29.8 |
| Week 8, Mild (n=30,68,43,104) | 36.7 | 23.5 | 23.3 | 26.0 |
| Week 8, Moderate (n=30,68,43,104) | 10.0 | 26.5 | 7.0 | 23.1 |
| Week 8, Severe (n=30,68,43,104) | 0.0 | 14.7 | 0.0 | 15.4 |
| Week 12, Clear (n=28,52,41,83) | 17.9 | 1.9 | 14.6 | 4.8 |
| Week 12, Almost Clear (n=28,52,41,83) | 35.7 | 19.2 | 58.5 | 32.5 |
| Week 12, Mild (n=28,52,41,83) | 32.1 | 36.5 | 22.0 | 24.1 |
| Week 12, Moderate (n=28,52,41,83) | 10.7 | 28.8 | 4.9 | 24.1 |
| Week 12, Severe (n=28,52,41,83) | 3.6 | 13.5 | 0.0 | 14.5 |
| Week 16, Clear (n=27,45,38,68) | 22.2 | 4.4 | 18.4 | 7.4 |
| Week 16, Almost Clear (n=27,45,38,68) | 33.3 | 28.9 | 52.6 | 25.0 |
| Week 16, Mild (n=27,45,38,68) | 18.5 | 22.2 | 21.1 | 25.0 |
| Week 16, Moderate (n=27,45,38,68) | 25.9 | 33.3 | 7.9 | 30.9 |
| Week 16, Severe (n=27,45,38,68) | 0.0 | 11.1 | 0.0 | 11.8 |
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline, Clear (n=27,75,42,120) | 22.2 | 2.7 | 19.0 | 5.0 |
| Baseline, Almost Clear (n=27,75,42,120) | 33.3 | 18.7 | 50.0 | 18.3 |
| Baseline, Mild (n=27,75,42,120) | 18.5 | 18.7 | 16.7 | 17.5 |
| Baseline, Moderate (n=27,75,42,120) | 25.9 | 37.3 | 14.3 | 33.3 |
| Baseline, Severe (n=27,75,42,120) | 0.0 | 22.7 | 0.0 | 25.8 |
| Week 4, Clear (n=27,74,42,118) | 18.5 | 5.4 | 19.0 | 10.2 |
| Week 4, Almost Clear (n=27,74,42,118) | 37.0 | 23.0 | 50.0 | 41.5 |
| Week 4, Mild (n=27,74,42,118) | 33.3 | 41.9 | 11.9 | 23.7 |
| Week 4, Moderate (n=27,74,42,118) | 11.1 | 25.7 | 14.3 | 20.3 |
| Week 4, Severe (n=27,74,42,118) | 0.0 | 4.1 | 4.8 | 4.2 |
| Week 8, Clear (n=26,71,41,118) | 19.2 | 7.0 | 19.5 | 15.3 |
| Week 8, Almost Clear (n=26,71,41,118) | 26.9 | 36.6 | 51.2 | 46.6 |
| Week 8, Mild (n=26,71,41,118) | 30.8 | 38.0 | 19.5 | 24.6 |
| Week 8, Moderate (n=26,71,41,118) | 19.2 | 16.9 | 7.3 | 9.3 |
| Week 8, Severe (n=26,71,41,118) | 3.8 | 1.4 | 2.4 | 4.2 |
| Week 16, Clear (n=22,65,38,101) | 13.6 | 10.8 | 18.4 | 20.8 |
| Week 16, Almost Clear (n=22,65,38,101) | 31.8 | 43.1 | 57.9 | 47.5 |
| Week 16, Mild (n=22,65,38,101) | 36.4 | 27.7 | 10.5 | 18.8 |
| Week 16, Moderate (n=22,65,38,101) | 13.6 | 13.8 | 5.3 | 10.9 |
| Week 16, Severe (n=22,65,38,101) | 4.5 | 4.6 | 7.9 | 2.0 |
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. Response defined as score of 0 or 1.
| percentage of participants | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 4 | 11.78 (8.31 to 15.26) | 21.19 (16.82 to 25.57) |
| Week 8 | 22.36 (17.87 to 26.84) | 45.37 (40.04 to 50.70) |
| Week 16 | 30.51 (25.55 to 35.47) | 54.63 (49.30 to 59.96) |
| Week 24 | 29.61 (24.69 to 34.53) | 51.64 (46.29 to 56.99) |
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. Response defined as score of 0 or 1.
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline (n=14,63,17,100) | 14.29 (0.00 to 32.62) | 6.35 (0.33 to 12.37) | 23.53 (3.37 to 43.69) | 8.00 (2.68 to 13.32) |
| Week 4 (n=14,63,17,100) | 21.43 (0.00 to 42.92) | 19.05 (9.35 to 28.74) | 35.29 (12.58 to 58.01) | 42.00 (32.33 to 51.67) |
| Week 8 (n=14,63,17,100) | 21.43 (0.00 to 42.92) | 34.92 (23.15 to 46.69) | 41.18 (17.78 to 64.57) | 54.00 (44.23 to 63.77) |
| Week 16 (n=14,63,17,100) | 21.43 (0.00 to 42.92) | 41.27 (29.11 to 53.43) | 58.82 (35.43 to 82.22) | 53.00 (43.22 to 62.78) |
The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5 point scale. The scale is scored as follows: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. Response defined as score of 0 or 1.
| percentage of participants | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Week 4 | 94.7 (68.1 to 99.2) | 50.7 (38.0 to 62.0) | 82.0 (65.9 to 91.0) | 55.5 (45.5 to 64.4) |
| Week 8 | 89.2 (63.1 to 97.2) | 32.8 (21.6 to 44.4) | 71.4 (54.3 to 83.0) | 33.3 (24.5 to 42.4) |
| Week 12 | 77.3 (50.1 to 90.8) | 21.3 (12.2 to 32.2) | 68.8 (51.6 to 80.9) | 24.2 (16.4 to 32.9) |
| Week 16 | 77.3 (50.1 to 90.8) | 16.0 (7.5 to 27.3) | 0.0 (NA to NA) | 0.0 (NA to NA) |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
| score on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Utility Score, Baseline (n=329,332) | 0.7 ± 0.0 | 0.7 ± 0.0 |
| Utility Score, Week 24 (n=270,272) | 0.8 ± 0.0 | 0.9 ± 0.0 |
| VAS, Baseline (n=329,332) | 69.9 ± 1.3 | 70.6 ± 1.3 |
| VAS, Week 24 (n=269,274) | 75.6 ± 1.2 | 80.3 ± 1.0 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
| score on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline Utility Score (n=27,75,42,120) | 0.8 ± 0.0 | 0.8 ± 0.0 | 0.9 ± 0.0 | 0.8 ± 0.0 |
| Week 56 Utility Score (n=22,65,34,96) | 0.9 ± 0.0 | 0.9 ± 0.0 | 0.9 ± 0.0 | 0.9 ± 0.0 |
| Baseline VAS (n=27,75,42,120) | 79.6 ± 3.4 | 76.5 ± 2.2 | 76.8 ± 3.5 | 75.3 ± 1.8 |
| Week 56 VAS (n=22,65,34,96) | 82.0 ± 2.5 | 82.3 ± 1.7 | 82.7 ± 2.7 | 83.8 ± 1.2 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. Baseline-A defined as the last observation up to first dosing date in Period A.
| scores on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Week 24 Utility Score (n=269,269) | 0.1 ± 0.0 | 0.2 ± 0.0 |
| Week 24 VAS (n=268, 271) | 5.3 ± 1.5 | 9.3 ± 1.4 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. Baseline-C defined as the last observation up to first dosing date in Period C.
| scores on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Week 56 Utility Score | 0.0 ± 0.0 | 0.1 ± 0.0 | -0.0 ± 0.0 | 0.1 ± 0.0 |
| Week 56 Visual Analogue Score | -1.0 ± 1.6 | 4.2 ± 1.7 | 6.4 ± 3.8 | 6.4 ± 1.5 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed").
| score on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Mobility, Baseline (n=329,332) | 1.3 ± 0.0 | 1.3 ± 0.0 |
| Mobility, Week 24 (n=270,274) | 1.2 ± 0.0 | 1.2 ± 0.0 |
| Self-Care, Baseline (n=330,332) | 1.1 ± 0.0 | 1.1 ± 0.0 |
| Self-Care, Week 24 (n=270,272) | 1.1 ± 0.0 | 1.0 ± 0.0 |
| Usual Activities Baseline (n=330,332) | 1.4 ± 0.0 | 1.4 ± 0.0 |
| Usual Activities Week 24 (n=270,273) | 1.2 ± 0.0 | 1.1 ± 0.0 |
| Pain/Discomfort Baseline (n=330,332) | 1.8 ± 0.0 | 1.9 ± 0.0 |
| Pain/Discomfort Week 24 (n=270,274) | 1.5 ± 0.0 | 1.4 ± 0.0 |
| Anxiety/Depression Baseline (n=330,332) | 1.4 ± 0.0 | 1.4 ± 0.0 |
| Anxiety/Depression Week 24 (n=270,274) | 1.3 ± 0.0 | 1.3 ± 0.0 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed").
| score on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Baseline Mobility (n=27,75,42,120) | 1.2 ± 0.1 | 1.2 ± 0.0 | 1.1 ± 0.1 | 1.2 ± 0.0 |
| Week 56 Mobility (n=22,65,34,96) | 1.2 ± 0.1 | 1.1 ± 0.0 | 1.1 ± 0.1 | 1.2 ± 0.0 |
| Baseline Self-Care (n=27,75,42,120) | 1.1 ± 0.1 | 1.1 ± 0.0 | 1.0 ± 0.0 | 1.1 ± 0.0 |
| Week 56 Self-Care (n=22,65,34,96) | 1.1 ± 0.1 | 1.0 ± 0.0 | 1.0 ± 0.0 | 1.0 ± 0.0 |
| Baseline Usual Activities (n=27,75,42,120) | 1.3 ± 0.1 | 1.2 ± 0.1 | 1.1 ± 0.1 | 1.3 ± 0.0 |
| Week 56 Usual Activities (n=22,65,34,96) | 1.1 ± 0.1 | 1.1 ± 0.0 | 1.1 ± 0.1 | 1.1 ± 0.0 |
| Baseline Pain/Discomfort (n=27,75,42,120) | 1.5 ± 0.1 | 1.6 ± 0.1 | 1.3 ± 0.1 | 1.7 ± 0.1 |
| Week 56 Pain/Discomfort (n=22,65,34,96) | 1.4 ± 0.1 | 1.5 ± 0.1 | 1.3 ± 0.1 | 1.4 ± 0.1 |
| Baseline Anxiety/Depression (n=27,75,42,120) | 1.3 ± 0.1 | 1.3 ± 0.1 | 1.2 ± 0.1 | 1.3 ± 0.0 |
| Week 56 Anxiety/Depression (n=22,65,34,96) | 1.2 ± 0.1 | 1.3 ± 0.1 | 1.2 ± 0.1 | 1.2 ± 0.0 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Baseline-A defined as the last observation up to first dosing date in Period A.
| scores on a scale | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Mobility (n=269,271) | -0.1 ± 0.0 | -0.1 ± 0.0 |
| Self-Care (n=270,269) | 0.0 ± 0.0 | -0.1 ± 0.0 |
| Usual Activities (n=270,270) | -0.1 ± 0.0 | -0.2 ± 0.0 |
| Pain / Discomfort (n=270,271) | -0.3 ± 0.0 | -0.5 ± 0.0 |
| Anxiety / Depression (n=270,271) | -0.1 ± 0.0 | -0.2 ± 0.0 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The score for each of the 5 dimensions can range from 1 to 3; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Baseline-C defined as the last observation up to first dosing date in Period C.
| scores on a scale | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Mobility | 0.0 ± 0.1 | -0.0 ± 0.0 | 0.0 ± 0.0 | -0.0 ± 0.0 |
| Self-Care | 0.0 ± 0.1 | -0.1 ± 0.0 | 0.0 ± 0.0 | -0.1 ± 0.0 |
| Usual Activities | -0.0 ± 0.0 | -0.1 ± 0.0 | 0.0 ± 0.0 | -0.2 ± 0.0 |
| Pain / Discomfort | 0.0 ± 0.1 | -0.1 ± 0.1 | 0.0 ± 0.1 | -0.3 ± 0.1 |
| Anxiety / Depression | -0.1 ± 0.1 | -0.1 ± 0.1 | 0.1 ± 0.1 | -0.1 ± 0.1 |
| percentage of participants | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) |
|---|---|---|
| Erythrodermic psoriasis | 0.0 | 0.6 |
| Guttate psoriasis | 0.0 | 0.0 |
| Pustular psoriasis | 0.0 | 0.3 |
| percentage of participants | CP-690,550 5 mg BID (Period B) | Placebo for 5 mg CP-690,550 BID (Period B) | CP-690,550 10 mg BID (Period B) | Placebo for 10 mg CP-690,550 BID (Period B) |
|---|---|---|---|---|
| Erythrodermic psoriasis | 0.0 | 0.0 | 0.0 | 0.0 |
| Guttate psoriasis | 0.0 | 0.0 | 0.0 | 0.8 |
| Pustular psoriasis | 0.0 | 0.0 | 0.0 | 0.0 |
| percentage of participants | CP-690,550 5 mg BID / CP-690,550 5 mg BID | Placebo BID / CP-690,550 5 mg BID | CP-690,550 10 mg BID / CP-690,550 10 mg BID | Placebo BID / CP-690,550 10 mg BID |
|---|---|---|---|---|
| Percentage of Participants With Pustular, Erythrodermic, or Guttate Psoriasis During CP-690,550 Re-Treatment (Period C) | 0.0 | 0.0 | 0.0 | 0.0 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CP-690,550 5 mg BID (Period A) | — | 6/218 (2.8%) | 101/218 (46.3%) |
| CP-690,550 10 mg BID (Period A) | — | 9/157 (5.7%) | 94/157 (59.9%) |
| CP-690,550 5 mg/CP-690,550 5 mg/CP-690,550 5 mg | — | 1/31 (3.2%) | 25/31 (80.6%) |
| CP-690,550 5 mg/Placebo/CP-690,550 5 mg | — | 3/82 (3.7%) | 65/82 (79.3%) |
| CP-690,550 10 mg/CP-690,550 10 mg/CP-690,550 10 mg | — | 4/45 (8.9%) | 41/45 (91.1%) |
| CP-690,550 10 mg / Placebo / CP-690,550 10 mg | — | 4/133 (3%) | 108/133 (81.2%) |
| Event | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) | CP-690,550 5 mg/CP-690,550 5 mg/CP-690,550 5 mg | CP-690,550 5 mg/Placebo/CP-690,550 5 mg | CP-690,550 10 mg/CP-690,550 10 mg/CP-690,550 10 mg | CP-690,550 10 mg / Placebo / CP-690,550 10 mg |
|---|---|---|---|---|---|---|
| Chest painGeneral disorders | 0/218 | 0/157 | 1/31 | 0/82 | 0/45 | 0/133 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/218 | 0/157 | 1/31 | 0/82 | 0/45 | 0/133 |
| BronchitisInfections and infestations | 0/218 | 0/157 | 0/31 | 0/82 | 1/45 | 0/133 |
| Peritonsillar abscessInfections and infestations | 0/218 | 0/157 | 0/31 | 0/82 | 1/45 | 0/133 |
| Traumatic lung injuryInjury, poisoning and procedural complications | 0/218 | 0/157 | 0/31 | 0/82 | 1/45 | 0/133 |
| DepressionPsychiatric disorders | 0/218 | 0/157 | 0/31 | 0/82 | 1/45 | 0/133 |
| Erythrodermic psoriasisSkin and subcutaneous tissue disorders | 0/218 | 2/157 | 0/31 | 0/82 | 0/45 | 0/133 |
| GoitreEndocrine disorders | 0/218 | 0/157 | 0/31 | 1/82 | 0/45 | 0/133 |
| HypomaniaPsychiatric disorders | 0/218 | 0/157 | 0/31 | 1/82 | 0/45 | 0/133 |
| NephrolithiasisRenal and urinary disorders | 0/218 | 0/157 | 0/31 | 1/82 | 0/45 | 0/133 |
| Event | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) | CP-690,550 5 mg/CP-690,550 5 mg/CP-690,550 5 mg | CP-690,550 5 mg/Placebo/CP-690,550 5 mg | CP-690,550 10 mg/CP-690,550 10 mg/CP-690,550 10 mg | CP-690,550 10 mg / Placebo / CP-690,550 10 mg |
|---|---|---|---|---|---|---|
| Blood creatine phosphokinase increasedInvestigations | 10/218 | 5/157 | 1/31 | 6/82 | 12/45 | 14/133 |
| NasopharyngitisInfections and infestations | 18/218 | 15/157 | 3/31 | 15/82 | 8/45 | 23/133 |
| Upper respiratory tract infectionInfections and infestations | 9/218 | 7/157 | 2/31 | 14/82 | 5/45 | 18/133 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 5/218 | 3/157 | 5/31 | 1/82 | 3/45 | 2/133 |
| HeadacheNervous system disorders | 6/218 | 6/157 | 2/31 | 5/82 | 4/45 | 17/133 |
| DiarrhoeaGastrointestinal disorders | 7/218 | 5/157 | 0/31 | 3/82 | 4/45 | 8/133 |
| Urinary tract infectionInfections and infestations | 7/218 | 5/157 | 1/31 | 6/82 | 4/45 | 9/133 |
| Blood cholesterol increasedInvestigations | 3/218 | 3/157 | 0/31 | 2/82 | 4/45 | 4/133 |
| Low density lipoprotein increasedInvestigations | 0/218 | 1/157 | 0/31 | 1/82 | 4/45 | 1/133 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 0/218 | 7/157 | 1/31 | 0/82 | 4/45 | 4/133 |
Full Analysis Set (FAS) included all participants who were randomized at baseline and received at least one dose of the randomized investigational drug (CP-690,550 5 mg BID or 10 mg BID) during Period A.
| Age, Continuous(years) | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) | CP-690,550 5 mg/CP-690,550 5 mg/CP-690,550 5 mg | CP-690,550 5 mg/Placebo/CP-690,550 5 mg | CP-690,550 10 mg/CP-690,550 10 mg/CP-690,550 10 mg | CP-690,550 10 mg / Placebo / CP-690,550 10 mg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 42.8 ± 13.0 | 45.6 ± 12.6 | 44.3 ± 13.0 | 45.2 ± 13.4 | 48.5 ± 14.8 | 46.1 ± 13.4 | 44.9 ± 13.2 |
| Sex: Female, Male(Participants) | CP-690,550 5 mg BID (Period A) | CP-690,550 10 mg BID (Period A) | CP-690,550 5 mg/CP-690,550 5 mg/CP-690,550 5 mg | CP-690,550 5 mg/Placebo/CP-690,550 5 mg | CP-690,550 10 mg/CP-690,550 10 mg/CP-690,550 10 mg | CP-690,550 10 mg / Placebo / CP-690,550 10 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 65 | 50 | 11 | 27 | 11 | 44 | 208 |
| Male | 153 | 107 | 20 | 55 | 34 | 89 | 458 |
The record gives a start of Sep 2010, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib